Tong A W; Stone M J
Cancer Immunology Research Laboratory, Baylor-Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas 75246, USA.
Leukemia & lymphoma (SWITZERLAND) Mar 1996, 21 (1-2) p1-8, ISSN 1042-8194 Journal Code: 9007422
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
CD40 is a 48 kDa glycosylated phospoprotein that is a member of the tumor necrosis factor receptor (TNF-R) superfamily. CD40 was originally identified in B lymphocytes, and is found on monocytes, dendritic cells, some carcinoma cell lines, and the thymic epithelium. CD40 is expressed on normal pre-B through mature B stages of differentiation. For normal B cells, the cross-linking of CD40 induces cell cycle progression, long-term proliferation in vitro, IgE secretion, increased adhesion molecule (LFA-1) expression, and low level IL-6 secretion. The natural ligand of CD40 (CD40L, gp39, or T-BAM, for T-B cell activating molecule) was recently identified as an inducible molecule expressed transitionally on activated T cells. Although originally believed to be absent in normal and malignant plasma cells, CD40 has been demonstrated on the majority of myeloma cell lines and myeloma cells from plasma cell dyscrasia (PCD) patient specimens tested. CD40 activation modulated myeloma cell proliferation and clonogenicity in vitro, suggesting that the CD40 pathway is active in myeloma cell growth. For the IL-6 dependent cell line ANBL-6, CD40 activation was associated with autocrine IL-6 production. However, the IL-6 pathway does not appear to play a predominant role in CD40 activation of non-IL-6-dependent MM cell lines and patient primary bone marrow cultures. The possible pathophysiologic role of the CD40 receptor in human multiple myeloma is discussed. (83 Refs.)
Record Date Created: 19970325
? t s9/kwic/2,1

409594
Gambel
AU 1644
8/26
09773866
733080
8/8/26

6/7/23 (Item 7 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09369928 97244166 PMID: 9088975
CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells.
Bjorck P; Banchereau J; Flores-Romo L
Schering-Plough Laboratory for Immunological Research, Dardilly, France.
International immunology (ENGLAND) Mar 1997, 9 (3) p365-72, ISSN 0953-8178 Journal Code: 8916182
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Dendritic cells (DC) are cells of the hematopoletic system specialized in capturing antigens and initiating T cell-mediated immune responses. We show here that human DC generated in vitro by culturing CD34+ cord blood progenitor cells in granulocyte macrophage colony stimulating factor plus tumor necrosis factor-alpha express the Fas antigen (APO-1, CD95) and undergo apoptosis upon triggering of Fas by mAb. However, only a proportion of the cells die in response to Fas ligation, an observation that may be related to the virtual absence of the bcl-2 protein in about half of the cells. Ligation of DC CD40 by culture on CD40L-transfected fibroblastic cells up-regulates the expression of bcl-2 and, concomitantly, renders DC virtually resistant to Fas-induced apoptosis. Parallel experiments with mature, interdigitating dendritic cells (IDC) isolated from tonsils revealed that IDC express Fas but do not enter into apoptosis following Fas ligation, a finding that may be explained by their high levels of bcl-2. Thus, upon encountering antigen-specific T cells, DC become resistant to Fas-induced apoptosis, as a consequence of CD40 ligation and possibly by mechanisms associated to the up-regulation of bcl-2 protein expression.
Record Date Created: 19971016

7/16 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

123110095 CA: 123(9)110095a JOURNAL
Stimulation of germinal center B lymphocyte proliferation by an FDC-like cell line, HK
AUTHOR(S): Kim, Han-Soo; Zhang, Xinhong; Klyushnenkova, Elena; Choi, Yong Sung
LOCATION: Lab. Cell. Immunol., Alton Ochsner Med. Foundation, New Orleans, LA, 70121, USA
JOURNAL: J. Immunol. DATE: 1995 VOLUME: 155 NUMBER: 3 PAGES: 1101-9
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English
SECTION:
CA215010 Immunochemistry
IDENTIFIERS: B cell proliferation follicular dendritic cell
DESCRIPTORS:
Animal cell line...
HK; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antigens,CD38... Apoptosis... Leukocyte,dendritic cell... Lymph node,germinal center... Lymphocyte,B-cell... Lymphokines and Cytokines,interleukin 4...
stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antibodies...
to IgM or CD40; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK

6/7/9 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

131270712 CA: 131(20)270712t JOURNAL
Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help
AUTHOR(S): Garcia de Vinuesa, Carola; MacLennan, Ian C. M.; Holman, Mary; Klaus, Gerry G. B.
LOCATION: Medical Research Council Center Immune Regulation, Univ. Birmingham, Birmingham, UK, B15 2TT
JOURNAL: Eur. J. Immunol. DATE: 1999 VOLUME: 29 NUMBER: 10 PAGES: 3216-3224 CODEN: EJIMAF ISSN: 0014-2980 LANGUAGE: English PUBLISHER: Wiley-VCH Verlag GmbH
SECTION:

6/7/6 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

07675635 EMBASE No: 1999150693
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
Kuniyoshi J.S.; Kuniyoshi C.J.; Lim A.M.; Wang F.Y.; Bade E.R.; Lau R.; Thomas E.K.; Weber J.S.
J.S. Kuniyoshi, Department of Molecular Microbiology, Univ. of S. California Sch. of Med., Los Angeles, CA 90033 United States
Cellular Immunology (CELL. IMMUNOL.) (United States) 10 APR 1999, 193/1 (48-58)
CODEN: CLIMB ISSN: 0008-8749
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 47

Dendritic cells (DC) are professional antigen-presenting cells which stimulate strong proliferative and cytolytic T cell responses. Stimulation of CD40 on dendritic cells by its ligands and anti-CD40 antibodies induces maturation and enhances DC stimulatory

Tong A W; Stone M J
Cancer Immunology Research Laboratory, Baylor-Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas 75246, USA.
Leukemia & lymphoma (SWITZERLAND) Mar 1996, 21 (1-2) p1-8, ISSN 1042-8194 Journal Code: 9007422
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

CD40 is a 48 kDa glycosylated phospoprotein that is a member of the tumor necrosis factor receptor (TNF-R) superfamily. CD40 was originally identified in B lymphocytes, and is found on monocytes, dendritic cells, some carcinoma cell lines, and the thymic epithelium. CD40 is expressed on normal pre-B through mature B stages of differentiation. For normal B cells, the cross-linking of CD40 induces cell cycle progression, long-term proliferation in vitro, IgE secretion, increased adhesion molecule (LFA-1) expression, and low level IL-6 secretion. The natural ligand of CD40 (CD40L, gp39, or T-BAM, for T-B cell activating molecule) was recently identified as an inducible molecule expressed transitionally on activated T cells. Although originally believed to be absent in normal and malignant plasma cells, CD40 has been demonstrated on the majority of myeloma cell lines and myeloma cells from plasma cell dyscrasia (PCD) patient specimens tested. CD40 activation modulated myeloma cell proliferation and clonogenicity in vitro, suggesting that the CD40 pathway is active in myeloma cell growth. For the IL-6 dependent cell line ANBL-6, CD40 activation was associated with autocrine IL-6 production. However, the IL-6 pathway does not appear to play a predominant role in CD40 activation of non-IL-6-dependent MM cell lines and patient primary bone marrow cultures. The possible pathophysiologic role of the CD40 receptor in human multiple myeloma is discussed. (83 Refs.)

Record Date Created: 19970325
? t s9/kwic/2,1

6/7/23 (Item 7 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09369928 97244166 PMID: 9088975
CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells.
Bjorck P; Banchereau J; Flores-Romo L
Schering-Plough Laboratory for Immunological Research, Dardilly, France.
International immunology (ENGLAND) Mar 1997, 9 (3) p365-72, ISSN 0953-8178 Journal Code: 8916182
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Dendritic cells (DC) are cells of the hematopoletic system specialized in capturing antigens and initiating T cell-mediated immune responses. We show here that human DC generated in vitro by culturing CD34+ cord blood progenitor cells in granulocyte macrophage colony stimulating factor plus tumor necrosis factor-alpha express the Fas antigen (APO-1, CD95) and undergo apoptosis upon triggering of Fas by mAb. However, only a proportion of the cells die in response to Fas ligation, an observation that may be related to the virtual absence of the bcl-2 protein in about half of the cells. Ligation of DC CD40 by culture on CD40L-transfected fibroblastic cells up-regulates the expression of bcl-2 and, concomitantly, renders DC virtually resistant to Fas-induced apoptosis. Parallel experiments with mature, interdigitating dendritic cells (IDC) isolated from tonsils revealed that IDC express Fas but do not enter into apoptosis following Fas ligation, a finding that may be explained by their high levels of bcl-2. Thus, upon encountering antigen-specific T cells, DC become resistant to Fas-induced apoptosis, as a consequence of CD40 ligation and possibly by mechanisms associated to the up-regulation of bcl-2 protein expression.

Record Date Created: 19971016

7/16 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

123110095 CA: 123(9)110095a JOURNAL
Stimulation of germinal center B lymphocyte proliferation by an FDC-like cell line, HK
AUTHOR(S): Kim, Han-Soo; Zhang, Xinhong; Klyushnenkova, Elena; Choi, Yong Sung
LOCATION: Lab. Cell. Immunol., Alton Ochsner Med. Foundation, New Orleans, LA, 70121, USA
JOURNAL: J. Immunol. DATE: 1995 VOLUME: 155 NUMBER: 3 PAGES: 1101-9
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English
SECTION:
CA215010 Immunochemistry
IDENTIFIERS: B cell proliferation follicular dendritic cell
DESCRIPTORS:
Animal cell line...
HK; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antigens,CD38... Apoptosis... Leukocyte,dendritic cell... Lymph node,germinal center... Lymphocyte,B-cell... Lymphokines and Cytokines,interleukin 4...
stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antibodies...
to IgM or CD40; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK

Gambel
AU 1644
8/26
09773866

NPL

6/7/9 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

131270712 CA: 131(20)270712t JOURNAL
Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help
AUTHOR(S): Garcia de Vinuesa, Carola; MacLennan, Ian C. M.; Holman, Mary; Klaus, Gerry G. B.
LOCATION: Medical Research Council Center Immune Regulation, Univ. Birmingham, Birmingham, UK, B15 2TT
JOURNAL: Eur. J. Immunol. DATE: 1999 VOLUME: 29 NUMBER: 10 PAGES: 3216-3224 CODEN: EJIMAF ISSN: 0014-2980 LANGUAGE: English PUBLISHER: Wiley-VCH Verlag GmbH
SECTION:

6/7/6 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

07675635 EMBASE No: 1999150693
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
Kuniyoshi J.S.; Kuniyoshi C.J.; Lim A.M.; Wang F.Y.; Bade E.R.; Lau R.; Thomas E.K.; Weber J.S.
J.S. Kuniyoshi, Department of Molecular Microbiology, Univ. of S. California Sch. of Med., Los Angeles, CA 90033 United States
Cellular Immunology (CELL. IMMUNOL.) (United States) 10 APR 1999, 193/1 (48-58)
CODEN: CLIMB ISSN: 0008-8749
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 47

Dendritic cells (DC) are professional antigen-presenting cells which stimulate strong proliferative and cytolytic T cell responses. Stimulation of CD40 on dendritic cells by its ligands and anti-CD40 antibodies induces maturation and enhances DC stimulatory

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

123110095 CA: 123(9)110095a JOURNAL
Stimulation of germinal center B lymphocyte proliferation by an FDC-like cell line, HK
AUTHOR(S): Kim, Han-Soo; Zhang, Xinhong; Klyushnenkova, Elena; Choi, Yong Sung
LOCATION: Lab. Cell. Immunol., Alton Ochsner Med. Foundation, New Orleans, LA, 70121, USA
JOURNAL: J. Immunol. DATE: 1995 VOLUME: 155 NUMBER: 3 PAGES: 1101-9
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English
SECTION:
CA215010 Immunochemistry
IDENTIFIERS: B cell proliferation follicular dendritic cell
DESCRIPTORS:
Animal cell line...
HK; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antigens,CD38... Apoptosis... Leukocyte,dendritic cell... Lymph node,germinal center... Lymphocyte,B-cell... Lymphokines and Cytokines,interleukin 4...
stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antibodies...
to IgM or CD40; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK

Gambel
Rec'd 16 44
09773866
8/26

NPL

6/7/9 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

131270712 CA: 131(20)270712t JOURNAL
Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help
AUTHOR(S): Garcia de Vinuesa, Carola; MacLennan, Ian C. M.; Holman, Mary; Klaus, Gerry G. B.
LOCATION: Medical Research Council Center Immune Regulation, Univ. Birmingham, Birmingham, UK, B15 2TT
JOURNAL: Eur. J. Immunol. DATE: 1999 VOLUME: 29 NUMBER: 10 PAGES: 3216-3224 CODEN: EJIMAF ISSN: 0014-2980 LANGUAGE: English PUBLISHER: Wiley-VCH Verlag GmbH
SECTION:

6/7/6 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

07675635 EMBASE No: 1999150693
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
Kuniyoshi J.S.; Kuniyoshi C.J.; Lim A.M.; Wang F.Y.; Bade E.R.; Lau R.; Thomas E.K.; Weber J.S.
J.S. Kuniyoshi, Department of Molecular Microbiology, Univ. of S. California Sch. of Med., Los Angeles, CA 90033 United States
Cellular Immunology (CELL. IMMUNOL.) (United States) 10 APR 1999, 193/1 (48-58)
CODEN: CLIMB ISSN: 0008-8749
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 47

Dendritic cells (DC) are professional antigen-presenting cells which stimulate strong proliferative and cytolytic T cell responses. Stimulation of CD40 on dendritic cells by its ligands and anti-CD40 antibodies induces maturation and enhances DC stimulatory

4/7/51 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10488448 20021827 PMID: 10553056

Generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-alpha, IL-1 beta, and **agonistic anti-CD40** monoclonal antibody.

Yamada N; Katz S I

Dermatology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Journal of immunology (Baltimore, Md. : 1950) (UNITED STATES) Nov 15 1999, 163 (10) p5331-7, ISSN 0022-1767 Journal Code: 2985117R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

We established a model system to generate mature dendritic cells (DC) from a GM-CSF-dependent cell line, XS52, which had been isolated from the epidermis of newborn BALB/c mice. Screening of various soluble factors revealed that IL-4 induces phenotypic maturation of XS52 (as evaluated by enhanced expression of class II, CD40, CD80, CD86, CD11c, and loss of expression of CD14) in a time-dependent manner. The addition of TNF-alpha, IL-1 beta, and **agonistic anti-CD40** mAb further enhanced expression of these maturation markers. Consistent with their phenotypic maturation, these cells (termed XS-DC) exhibited potent Ag-presenting capacity to both naive and primed T cells. In addition, injection of hapten-conjugated XS-DC induced contact hypersensitivity in vivo, suggesting their potential as tools for vaccination. Expression of CD14 by the starting cell population, the requirement for GM-CSF and IL-4, and the relatively long culture period are the common characteristics shared between our cells and human monocyte-derived DC, whose analogues in mice have not been identified. Because large numbers of skin-associated mature DC devoid of other cell lineages are easily obtained, this model system may facilitate the study of molecular events associated with maturation of DC and the use of DC for immunization.

Record Date Created: 19991202

4/7/46 (Item 15 from file: 73)
DIALOG(R)File 73:EMBASE

07735425 EMBASE No: 1999217763

CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion

Maxwell J.R.; Campbell J.D.; Kim C.H.; Vella A.T.
Dr. A.T. Vella, 220 Nash Hall, Department of Microbiology, Oregon State University, Corvallis, OR 97331 United States
AUTHOR EMAIL: vellaa@bcc.orst.edu

Journal of Immunology (J. IMMUNOL.) (United States) 15 FEB 1999, 162/4 (2024-2034)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 87

In this report we show that activation of APC with an **agonist anti-CD40** mAb profoundly alters the behavior of CD4 T cells in vivo. Stimulation of mice with anti-CD40 2 days before, but not 1 day after, administration of superantigen (SAg) enhanced CD4 and CD8 T cell clonal expansion by approximately threefold. Further, CD40 activation also delayed peripheral T cell deletion after activation. Dying, activated T cells were quantitated by detecting extracellular phosphatidylserine with concomitant staining for SAg- reactive T cells using a TCR Vbeta-specific mAb. Upon close examination, it was shown that CD40 activation delayed the death of the activated T cells. Additionally, it was found that enhanced survival of CD4 T cells was equally dependent on APC expression of B7-1 and B7-2. This is in contrast to CD8 T cells, which did not depend as much on B7-1 as B7-2. Thus, CD40 activation indirectly promotes T cell growth and delays the death of SAg-stimulated CD4 T cells in vivo. These data suggest that one way CD40 activation promotes a more robust immune response is by indirectly increasing the production of effector T cells and by keeping them alive for longer periods of time.

09436213 BIOSIS NO.: 199497444583
Monoclonal antibodies to murine CD40 define two distinct functional epitopes.
AUTHOR: Heath Andrew W; Wu Wei Wei; Howard Maureen C(a)
AUTHOR ADDRESS: (a)DNAX Res. Inst., 901 California Ave., Palo Alto, CA 94304**USA
JOURNAL: European Journal of Immunology 24 (8):p1828-1834 1994
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Two rat IgG-2a antibodies which define distinct epitopes on murine CD40 have been generated. These antibodies specifically bind recombinant murine CD40 expressed on L cells, and the soluble extracellular domain of murine CD40 coated onto microtiter plates. Both antibodies bind B220+ but not B220 murine spleen cells, and immunoprecipitate a 45-kDa protein from the surface of purified murine splenic B cells. These antibodies exhibit separate functional properties, consistent with the notion that they define two distinct CD40 epitopes. One of the monoclonal antibodies (designated 1C10) directly induces a specific proliferative response from mature immune B cells, up-regulates several B cell surface antigens, and rescues immature B lymphoma cells from anti-IgM-induced growth arrest. The other monoclonal antibody (designated 4F11) exhibits none of these properties, but is capable of synergizing with suboptimal amounts of either anti-IgM antibodies or the 1C10 **agonistic anti-CD40** antibody to produce an optimal proliferative response of purified small dense B cells. Furthermore, 4F11 antibody synergizes with suboptimal amounts of 1C10 antibody to rescue B lymphoma cells from anti-IgM-induced growth arrest. The 1C10 and 4F11 antibodies were unable to cross-block each other's binding to recombinant CD40 expressed in L cells, providing strong support for the notion that the antibodies recognize distinct epitopes on CD40. The potential implications of two functionally distinct CD40 epitopes are discussed.

11403258 BIOSIS NO.: 199800184590
The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb.
AUTHOR: Ferlin Walter G; Von Der Weid Thierry; Cottrez Francoise; Ferrick David A; Coffman Robert L; Howard Maureen C(a)
AUTHOR ADDRESS: (a)Anergen Inc., 301 Penobscot Dr., Redwood City, CA 94036 **USA
JOURNAL: European Journal of Immunology 28 (2):p525-531 Feb., 1998
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: A protective immune response to the intracellular parasite Leishmania major requires the development of a Th1 CD4+ T cell phenotype. We demonstrate herein that BALB/c mice, which normally develop a susceptible Th2 response to L. major infection, are protected when co-injected with an **agonistic** anti-murine CD40 mAb. **Anti-CD40** mAb-mediated protection in this system was found to be T cell dependent, since it was not observed in C57BU 6 X 129 mice that were rendered T cell deficient (TCR beta-/- X TCR delta-/-) and L. major susceptible. Anti-CD40 mAb stimulation of L. major-infected BALB/c mice was accompanied by increased IL-12 and IFN-gamma production in draining lymph nodes, analyzed either by direct expression, or in an antigen-specific in vitro recall assay. The protective role of these cytokines was indicated by the finding that anti-CD40 mAb-mediated protection of L. major-infected BALB/c mice could be reversed by co-treating the animals with neutralizing anti-IL-12 and/or anti-IFN-gamma mAb. Collectively, these data suggest that BALB/c mice develop a protective Th1 CD4+ T cell response to L. major infection when co-injected with anti-CD40 mAb. While the CD40-CD40L interaction has been previously shown to be vital in the control of murine Leishmaniasis, the current study establishes in vivo that anti-CD40 mAb treatment alone is sufficient to protect BALB/c mice from L. major infection and raises the possibility of utilizing this approach for vaccination strategies.

WEST

Generate Collection Print

L2: Entry 7 of 10 File: USPT Mar 2, 1999

DOCUMENT-IDENTIFIER: US 5876950 A
TITLE: Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy

Brief Summary Text (4):
CD40 is a 50 kDa type I membrane glycoprotein expressed by B cells, macrophages, follicular dendritic cells, thymic epithelium, normal basal epithelium, some carcinoma and melanoma-derived cell lines (Clark and Ledbetter 1986, Proc. Nat'l. Acad. Sci. USA 83:4494; Paerlie et al. 1985, Cancer Immunol. Immunother. 20:23, Ledbetter et al. 1987, J. Immunol. 138:788; Young et al. 1989, Int. J. Cancer 43:786; Galy and Spits 1992, J. Immunol. 149:775, Alderson et al. 1993, J. Exp. Med 178:669) and recently has been reported to be expressed on T cells (Armitage et al. 1993, Eur. J. Immunol. 23: 2326). It has been shown to be an important signaling molecule with a range of downstream effects in multiple systems. Early studies showed that CD40 was involved in B cell activation. Crosslinking CD40 with anti-CD40 monoclonal antibody induces B cell aggregation via LFA-1 (Gordon et al. 1988, J. Immunol. 140:1425, Barrett et al., 1991, J. Immunol. 146:1722), increases Ser/Thr (Gordon et al. 1988, supra) and Tyr (Uckun et al. 1991, J. Biol. Chem. 266:17478) phosphorylation of a number of intracellular substrates and provides a "competence" signal that allows B cells to proliferate and undergo class switching when stimulated with the appropriate second signal. For example, anti-CD40 monoclonal antibody can synergize with PMA (Gordon et al. 1987, Eur. J. Immunol. 17:1535) or anti-CD20 monoclonal antibody (Clark and Ledbetter 1986, supra) to induce B cell proliferation, with IL-4 to induce B cell proliferation (Gordon et al. 1987, supra; Rousset et al. 1991, J. Exp. Med. 172:705) and IgE secretion (Jabara et al. 1990, J. Exp. Med. 172:1861; Gascan et al. 1991, J. Immunol. 147:8; Rousset et al. 1991, supra; Zhang et al. 1991, J. Immunol. 146.1836, Shapira et al. 1992, J. Exp. Med. 175:289) and with IL-10 and TGF-.beta. to induce IgA secretion by sIgD.sup.+ B cells (DeFrance et al. 1992, J. Exp. Med. 175:671).

```
ds

Set      Items    Description
S1           9    (3(W)23)(10N)(ANTIBOD?)(10N)(CD40)
S2           4    RD S1 (unique items)
S3           0    (CD40)(10N)(ANTIBOD?)(DENDRITIC)
S4          88    (CD40)(10N)(ANTIBOD?)(10N)(DENDRITIC)
S5          66    RD S4 (unique items)
S6          25    S5 AND PY<2000
S7         398    ANTI(W)CD40(20N)(HUMAN?)
S8          14    S7 AND DENDRITIC
S9          11    RD S8 (unique items)
S10          5    5C11 (20N) ANTIBOD? (20N) (CD40)
S11          2    RD S10 (unique items)
?
```

6/7/7 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

132346395 CA: 132(26)346395k JOURNAL
Obtaining of anti-human CD40 mono-clonal antibody with special functions and analysis of it's biological effects
AUTHOR(S): Zhou, Zhaohua; Wang, Jiangfang; Wang, Yuedan; Qiu, Yuhua; Pan, Jianzhong; Xie, Wei; Jiang, Lingyu; Zhang, Xueguang
LOCATION: Department of Immunology, Suzhou Medical College, Suzhou, Peop. Rep. China, 215007
JOURNAL: Zhongguo Mianyixue Zazhi DATE: 1999 VOLUME: 15 NUMBER: 12
PAGES: 529-533 CODEN: ZMZAEE ISSN: 1000-484X LANGUAGE: Chinese
PUBLISHER: Zhongguo Mianyixue Zazhi Bianjibu
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: monoclonal antibody CD40 dendritic cell lymphocyte
DESCRIPTORS:
Cell proliferation...
B cell; prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects
Antibodies...
monoclonal; prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects
CD40(antigen)...
prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects
Dendritic cell...
prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects in relation to
B cell(lymphocyte)...
proliferation; prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects

```
 ds

Set      Items    Description
S1           9    (3(W)23)(10N)(ANTIBOD?)(10N)(CD40)
S2           4    RD S1 (unique items)
S3           0    (CD40)(10N)(ANTIBOD?)(DENDRITIC)
S4          88    (CD40)(10N)(ANTIBOD?)(10N)(DENDRITIC)
S5          66    RD S4 (unique items)
S6          25    S5 AND PY<2000
S7         398    ANTI(W)CD40(20N)(HUMAN?)
S8          14    S7 AND DENDRITIC
S9          11    RD S8 (unique items)
S10          5    5C11 (20N) ANTIBOD? (20N) (CD40)
S11          2    RD S10 (unique items)
? ds

Set      Items    Description
S1           9    (3(W)23)(10N)(ANTIBOD?)(10N)(CD40)
S2           4    RD S1 (unique items)
S3           0    (CD40)(10N)(ANTIBOD?)(DENDRITIC)
S4          88    (CD40)(10N)(ANTIBOD?)(10N)(DENDRITIC)
S5          66    RD S4 (unique items)
S6          25    S5 AND PY<2000
S7         398    ANTI(W)CD40(20N)(HUMAN?)
S8          14    S7 AND DENDRITIC
S9          11    RD S8 (unique items)
S10          5    5C11 (20N) ANTIBOD? (20N) (CD40)
```

PATENT: PCT International ; WO 9513089 A1 DATE: 950518
APPLICATION: WO 94US12802 (941108) *US 150510 (931110) *US 315492 (940930)
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/19A; C07K-017/10B; C07K-014/52B DESIGNATED COUNTRIES: AU; CA; JP
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

9/3/105 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

122078853 CA: 122(7)78853n JOURNAL
IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation
AUTHOR(S): Armitage, Richard J.; Macduff, Brian M.; Eisenman, June; Paxton, Raymond; Grabstein, Kenneth H.
LOCATION: Departments of Cellular Immunology and Protein Chemistry, Immunex Research and Development Corporation, Seattle, WA, 98101, USA
JOURNAL: J. Immunol. DATE: 1995 VOLUME: 154 NUMBER: 2 PAGES: 483-90
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English

9/3/106 (Item 19 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

119093523 CA: 119(9)93523m PATENT
Murine and human cytokine (CD40-L) which binds to CD40, and soluble CD40 and CD40 fusion molecules
INVENTOR(AUTHOR): Armitage, Richard J.; Fanslow, William C.; Spriggs, Melanie K.
LOCATION: USA
ASSIGNEE: Immunex Corp.
PATENT: PCT International ; WO 9308207 A1 DATE: 930429
APPLICATION: WO 92US8990 (921023) *US 783707 (911025) *US 805723 (911205)
PAGES: 79 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07H-021/00A; A61K-035/14B; C07K-003/00B; C07K-007/00B; C07K-013/00B; C12P-021/02B; C12P-021/06B; C12N-015/00B DESIGNATED COUNTRIES: AU; CA; FI; JP; KR; NO
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; SE
?

```
      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399
       25aug02 08:13:33 User208760 Session D2134.2
            $0.00    0.070 DialUnits File410
     $0.00  Estimated cost File410
     $0.01  TELNET
     $0.01  Estimated cost this search
     $0.27  Estimated total session cost   0.145 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R)  1969-2002/Aug W2
         (c) 2002 BIOSIS
*File   5: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File  73:EMBASE  1974-2002/Aug W3
         (c) 2002 Elsevier Science B.V.
*File  73: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File 155:MEDLINE(R)  1966-2002/Aug W3
*File 155: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File 399:CA SEARCH(R)  1967-2002/UD=13708
         (c) 2002 AMERICAN CHEMICAL SOCIETY
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.

      Set  Items  Description
      ---  -----  -----------
? e au=thomas david /

Ref    Items  Index-term
E1         1  AU=THOMAS DAVE Y
E2        65  AU=THOMAS DAVID
E3         0 *AU=THOMAS DAVID /
E4        16  AU=THOMAS DAVID A
E5        54  AU=THOMAS DAVID B
E6         4  AU=THOMAS DAVID B L
E7         3  AU=THOMAS DAVID BRYNMOR
E8        18  AU=THOMAS DAVID C
E9       155  AU=THOMAS DAVID D
E10        7  AU=THOMAS DAVID F M
E11        9  AU=THOMAS DAVID G
E12       33  AU=THOMAS DAVID G T

          Enter P or PAGE for more
? p

Ref    Items  Index-term
E13        1  AU=THOMAS DAVID GT
E14        9  AU=THOMAS DAVID H
E15        3  AU=THOMAS DAVID H L
E16       52  AU=THOMAS DAVID J
E17        1  AU=THOMAS DAVID K
E18       92  AU=THOMAS DAVID L
E19       16  AU=THOMAS DAVID M
E20        2  AU=THOMAS DAVID MORGAN
E21       13  AU=THOMAS DAVID N
E22        2  AU=THOMAS DAVID P
E23       36  AU=THOMAS DAVID R
```

```
E24        1  AU=THOMAS DAVID S

           Enter P or PAGE for more
? p

Ref    Items  Index-term
E25        3  AU=THOMAS DAVID S G
E26        1  AU=THOMAS DAVID T
E27       31  AU=THOMAS DAVID W
E28      109  AU=THOMAS DAVID Y
E29        1  AU=THOMAS DAVIS B
E30        2  AU=THOMAS DAWN M
E31        1  AU=THOMAS DAWNEY
E32        1  AU=THOMAS DE LABARTHE B D
E33        1  AU=THOMAS DE LABARTHE J D E
E34        8  AU=THOMAS DE MONTPREVILLE V
E35        5  AU=THOMAS DE MONTPREVILLE V.
E36        2  AU=THOMAS DE MONTPREVILLE, C.

           Enter P or PAGE for more
? s e1-e28
                1  AU=THOMAS DAVE Y
               65  AU=THOMAS DAVID
                0  AU=THOMAS DAVID /
               16  AU=THOMAS DAVID A
               54  AU=THOMAS DAVID B
                4  AU=THOMAS DAVID B L
                3  AU=THOMAS DAVID BRYNMOR
               18  AU=THOMAS DAVID C
              155  AU=THOMAS DAVID D
                7  AU=THOMAS DAVID F M
                9  AU=THOMAS DAVID G
               33  AU=THOMAS DAVID G T
                1  AU=THOMAS DAVID GT
                9  AU=THOMAS DAVID H
                3  AU=THOMAS DAVID H L
               52  AU=THOMAS DAVID J
                1  AU=THOMAS DAVID K
               92  AU=THOMAS DAVID L
               16  AU=THOMAS DAVID M
                2  AU=THOMAS DAVID MORGAN
               13  AU=THOMAS DAVID N
                2  AU=THOMAS DAVID P
               36  AU=THOMAS DAVID R
                1  AU=THOMAS DAVID S
                3  AU=THOMAS DAVID S G
                1  AU=THOMAS DAVID T
               31  AU=THOMAS DAVID W
              109  AU=THOMAS DAVID Y
      S1      737  E1-E28
? s s1 and cd40
              737  S1
            15418  CD40
      S2       11  S1 AND CD40
? rd s2
...completed examining records
      S3       11  RD S2 (unique items)
? t s3/7/all

 3/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12450297   BIOSIS NO.: 200000203799
```

Readministration of adenovirus vector in nonhuman primate lungs by blockade of **CD40-CD40** ligand interactions.
AUTHOR: Chirmule Narendra; Raper Steven E; Burkly Linda; **Thomas David** ; Tazelaar John; Hughes Joseph V; Wilson James M(a
AUTHOR ADDRESS: (a)University of Pennsylvania, 3601 Spruce St., 204 Wistar Institute, Philadelphia, PA, 19104**USA
JOURNAL: Journal of Virology 74 (7):p3345-3352 April, 2000
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: The interaction between **CD40** on B cells and **CD40** ligand (CD40L) on activated T cells is important for B-cell differentiation in T-cell-dependent humoral responses. We have extended our previous murine studies of **CD40**-CD40L in adenoviral vector-mediated immune responses to rhesus monkeys. Primary immune responses to adenoviral vectors and the ability to readminister vector were studied in rhesus monkeys in the presence or absence of a transient treatment with a humanized anti-**CD40** ligand antibody (hu5C8). Adult animals were treated with hu5C8 at the time vector was instilled into the lung. Immunological analyses demonstrated suppression of adenovirus-induced lymphoproliferation and cytokine responses (interleukin-2 (IL-2), gamma interferon, IL-4, and IL-10) in hu5C8-treated animals. Animals treated with hu5C8 secreted adenovirus-specific immunoglobulin M (IgM) levels comparable to control animals, but did not secrete IgA or develop neutralizing antibodies; consequently, the animals could be readministered with adenovirus vector expressing alkaline phosphatase. A second study was designed to examine the long-term effects on immune functions of a short course of hu5C8. Acute hu5C8 treatment resulted in significant and prolonged inhibition of the adenovirus-specific humoral response well beyond the time hu5C8 effects were no longer significant. These studies demonstrate the potential of hu5C8 as an immunomodulatory regimen to enable administration of adenoviral vectors, and they advocate testing this model in humans.

3/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12330253 BIOSIS NO.: 200000083755
Prolongation of primate cardiac allograft survival by treatment with anti-**CD40** ligand (CD154) antibody.
AUTHOR: Pierson Richard N III(a); Chang Andrew C; Blum Matthew G; Blair Kelly S A; Scott Margie A; Atkinson James B; Collins Brendan J; Zhang Jian-Ping; **Thomas David W**; Burkly Linda C; Miller Geraldine G
AUTHOR ADDRESS: (a)Division of Cardiac and Thoracic Surgery, Vanderbilt University Medical Center, 2986 Vanderbilt Clinic, Nashville, TN, 37232-5734**USA
JOURNAL: Transplantation (Baltimore) 68 (11):p1800-1805 Dec. 15, 1999
ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Background: We evaluated whether a humanized anti-CD154 antibody (hu5c8) prolongs primate cardiac allograft survival. Methods: Heterotopic cardiac allografts were performed between MHC class II-mismatched cynomolgus monkeys. Survival was compared between groups treated with a perioperative dosing of hu5c8 (group 1; n=6), sustained dosing with hu5c8

(group 2; n=3), and control regimens (n=4). All recipients received fresh donor-specific transfusions during surgery. Results: Median graft survival was 49 days (range 14 to 56) in group 1 and 106 days (range 56 to 245) in group 2, compared with 5 days (range 5 to 6) for controls (P<0.05 for all comparisons). Lymphocytic infiltrates were often present in hu5c8-treated grafts with stable contractility. Donor-specific mixed lymphocyte reaction was generally preserved. Vasculitis and cellular intimal proliferation were prevalent in rejected grafts but occurred later and were less prevalent in group 2. Conclusions: Anti-CD154 antibody markedly prolongs the survival of cardiac allografts in primates and is well tolerated. Sustained dosing with hu5c8 yielded improved survival and may be associated with a lower incidence of vascular pathology. We conclude that hu5c8 therapy is an effective approach for inhibiting acute cardiac allograft rejection in primates.

3/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12052984 BIOSIS NO.: 199900333503
An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM syndrome).
AUTHOR: Webster Elizabeth A; Khakoo Aarif Y; Mackus Wendeline JM; Karpusas Michael; **Thomas David W**; Davidson Anne; Christian Charles L; Lederman Seth(a
AUTHOR ADDRESS: (a)Laboratory of Molecular Immunology, Columbia University, 630 West 168th Street, PH8-405, New Yor**USA
JOURNAL: Arthritis & Rheumatism 42 (6):p1291-1296 June, 1999
ISSN: 0004-3591
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Hyper-IgM syndrome (HIM) is a rare immunodeficiency disorder that has been associated with the development of symptoms and clinical features characteristic of rheumatoid arthritis (RA). We describe a patient with HIM and severe erosive arthritis with prominent nodules in the absence of detectable serum rheumatoid factor. Because HIM results from defects in either T cell CD154 (**CD40** ligand) expression or abnormal **CD40** signaling, the molecular basis of the patient's disease was analyzed. Activated CD4+ T cells failed to express surface CD154 protein, and molecular analysis of CD154 complementary DNA revealed a nucleotide transversion resulting in the nonconservative amino acid substitution G-D at amino acid 257. This case indicates that defective CD154-dependent **CD40** signaling can be associated with susceptibility to a severe inflammatory arthritis that has both similarities to and differences from idiopathic RA.

3/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11657035 BIOSIS NO.: 199800438766
Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (**CD40** ligand) suppression of an immune response in monkeys.
AUTHOR: Gobburu Jogarao V S; Tenhoor Christopher; Rogge Mark C; Frazier Donald E Jr; **Thomas David**; Benjamin Chris; Hess Donna M; Jusko William J(a
AUTHOR ADDRESS: (a)545 Hochstetter Hall, Dep. Pharm., SUNY, Buffalo, NY 14260**USA
JOURNAL: Journal of Pharmacology and Experimental Therapeutics 286 (2):p

925-930 Aug., 1998
ISSN: 0022-3565
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The pharmacokinetics and pharmacodynamics (PK/PD) of chimeric (Ch5c8) and humanized (Hu5c8) 5c8, a monoclonal antibody that binds CD154 (**CD40** ligand), thus blocking the interaction between **CD40** and CD154, were investigated in cynomolgus monkeys. Single-dose groups (n= 3 animals per dose) received saline, 0.2, 1, 5 or 20 mg/kg i.v. doses of Hu5c8. The repeat-dose groups (n = 4 animals) received 0 or 5 mg/kg i.v. doses of Ch5c8 or Hu5c8 on days 1, 2, 3, 5, 7 and 9. The single-dose PK parameters showed dose proportionality, with a terminal half-life of 300 h, a volume of distribution at steady state of 73 ml/kg and clearance of 0.2 mlcntdoth-1cntdotkg-1. The repeat-dose regimen produced a longer terminal half-life (500 h) and lower clearance (0.13 mlcntdoth-1cntdotkg-1) than in the single-dose groups. The antibody titer to tetanus toxoid (ATT) challenge served as the immunodynamic marker. The primary ATT response consisted of a latent phase of apprx10 days, during which the immune system was processing antigen but not yet producing antibody, a rise to an antibody maximum titer at apprx18 days and a decline toward baseline by apprx40 days in controls. The 5c8 produced a log(dose)-proportional reduction in the area under the curve of ATT. An indirect PK/PD model based on the kinetics of tetanus toxoid exposure and inhibition of ATT production in relation to 5c8 concentrations was developed. A median inhibitory concentration of 0.84 mug/ml and a efficacy of 0.84 reflected marked inhibition of ATT response by 5c8. The model provides quantitation of reduced ATT responses after 5c8 and was applicable to primary and secondary immune responses and to both single-dose and multiple-dose treatments. The monoclonal antibody 5c8 blocks the **CD40** and CD154 interaction, producing consistent and substantive reduction in antibody formation after administration of tetanus toxoid, which can be characterized with PK/PD modeling. It is anticipated that 5c8 may have utility in the treatment of antibody-mediated autoimmune disease.

3/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11490917 BIOSIS NO.: 199800272249
The role of polar interactions in the molecular recognition of CD40L with its receptor **CD40**.
AUTHOR: Singh Juswinder(a); Garber Ellen; Van Vlijmen Herman; Karpusas Michael; Hsu Yen-Ming; Zheng Zhongli; Naismith James H; **Thomas David**
AUTHOR ADDRESS: (a)Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142** USA
JOURNAL: Protein Science 7 (5):p1124-1135 May, 1998
ISSN: 0961-8368
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: **CD40** Ligand (CD40L) is transiently expressed on the surface of T-cells and binds to **CD40**, which is expressed on the surface of B-cells. This binding event leads to the differentiation, proliferation, and isotype switching of the B-cells. The physiological importance of CD40L has been demonstrated by the fact that expression of defective CD40L protein causes an immunodeficiency state characterized by high IgM and low IgG serum levels, indicating faulty T-cell dependent B-cell activation. To understand the structural basis for CD40L/**CD40**

association, we have used a combination of molecular modeling, mutagenesis, and X-ray crystallography. The structure of the extracellular region of CD40L was determined by protein crystallography, while the **CD40** receptor was built using homology modeling based upon a novel alignment of the TNF receptor superfamily, and using the X-ray structure of the TNF receptor as a template. The model shows that the interface of the complex is composed of charged residues, with CD40L presenting basic side chains (K143, R203, R207), and **CD40** presenting acidic side chains (D84, E114, E117). These residues were studied experimentally through site-directed mutagenesis, and also theoretically using electrostatic calculations with the program Delphi. The mutagenesis data explored the role of the charged residues in both CD40L and **CD40** by switching to Ala (K143A, R203A, R207A of CD40L, and E74A, D84A, E114A, E117A of **CD40**), charge reversal (K143E, R203E, R207E of CD40L, and D84R, E114R, E117R of **CD40**), mutation to a polar residue (K143N, R207N, R207Q of CD40L, and D84N, E117N of **CD40**), and for the basic side chains in CD40L, isosteric substitution to a hydrophobic side chain (R203M, R207M). All the charge-reversal mutants and the majority of the Met and Ala substitutions led to loss of binding, suggesting that charged interactions stabilize the complex. This was supported by the Delphi calculations which confirmed that the **CD40**/CD40L residue pairs E74-R203, D84-R207, and E117-R207 had a net stabilizing effect on the complex. However, the substitution of hydrophilic side chains at several of the positions was tolerated, which suggests that although charged interactions stabilize the complex, charge per se is not crucial at all positions. Finally, we compared the electrostatic surface of TNF/TNFR with CD40L/**CD40** and have identified a set of polar interactions surrounded by a wall of hydrophobic residues that appear to be similar but inverted between the two complexes.

3/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11420349 BIOSIS NO.: 199800201681
Effect of anti-CD40L antibody on the host response to Streptococcus pneumoniae.
AUTHOR: Hwang Young-Il(a); Briles David E; **Thomas David W**; Nahm Moon H
AUTHOR ADDRESS: (a)Univ. Rochester, Rochester, NY 14642**USA
JOURNAL: FASEB Journal 12 (4):pA570 March 17, 1998
CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists on Experimental Biology 98, Part 1 San Francisco, California, USA April 18-22, 1998
SPONSOR: Federation of American Societies for Experimental Biology
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English

3/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11090776 BIOSIS NO.: 199799711921
CTLA4-Ig and anti-**CD40** ligand prevent renal allograft rejection in primates.
AUTHOR: Kirk Allan D(a); Harlan David M; Armstrong Nicholas N; Davis Thomas A; Dong Yinchen; Gray Gary S; Hong Xuening; **Thomas David**; Fechner John H Jr; Knechtle Stuart J
AUTHOR ADDRESS: (a)Division Transplantation, Univ. Wisconsin Hosp., Madison, WI 53792**USA

JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 94 (16):p8789-8794 1997
ISSN: 0027-8424
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Selective inhibition of T cell costimulation using the B7-specific fusion protein CTLA4-Ig has been shown to induce long-term allograft survival in rodents. Antibodies preventing the interaction between **CD40** and its T cell-based ligand CD154 (CD40L) have been shown in rodents to act synergistically with CTLA4-1g. It has thus been hypothesized that these agents might be capable of inducing long-term acceptance of allografted tissues in primates. To test this hypothesis in a relevant preclinical model, CTLA4-Ig and the CD40L-specific monoclonal antibody 5C8 were tested in rhesus monkeys. Both agents effectively inhibited rhesus mixed lymphocyte reactions, but the- combination was 100 times more effective than either drug alone. Renal allografts were transplanted into nephrectomized rhesus monkeys shown to be disparate at major histocompatibility complex class I and class II loci. Control animals rejected in 5-8 days. Brief induction doses of CTLA4-Ig or 5C8 alone significantly prolonged rejection-free survival (20-98 days). Two of four animals treated with both agents experienced extended (gt 150 days) rejection-free allograft survival. Two animals treated with 5C8 alone and one animal treated with both 5C8 and CTLA4-Ig experienced late, biopsy-proven rejection, but a repeat course of their induction regimen successfully restored normal graft function. Neither drug affected peripheral T cell or B cell counts. There were no clinically evident side effects or rejections during treatment. We conclude that CTLA4-Ig and 5C8 can both prevent and reverse acute allograft rejection, significantly prolonging the survival of major histocompatibility complex-mismatched renal allografts in primates without the need for chronic immunosuppression.

3/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10821727 BIOSIS NO.: 199799442872
CD40-CD40L interactions are critical in immune responses of both cell-mediated and humoral immune responses to adenoviral vectors in non-human primates.
AUTHOR: Chirmule Narendra(a); Raper Stevens E(a); Hess Donna; **Thomas David W**; Wilson James M(a
AUTHOR ADDRESS: (a)Univ. Pa., Philadelphia, PA**USA
JOURNAL: Journal of Allergy and Clinical Immunology 99 (1 PART 2):pS36 1997
CONFERENCE/MEETING: Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA February 21-26, 1997
ISSN: 0091-6749
RECORD TYPE: Citation
LANGUAGE: English

3/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10738558 BIOSIS NO.: 199799359703
Heteromultimeric complexes of **CD40** ligand are present on the cell surface of human T lymphocytes.
AUTHOR: Hsu Yen-Ming(a); Lucci Jodie; Su Lihe; Ehrenfels Barbara; Garber

Ellen; **Thomas David**
AUTHOR ADDRESS: (a)Dep. Protein Eng., Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142**USA
JOURNAL: Journal of Biological Chemistry 272 (2):p911-915 1997
ISSN: 0021-9258
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: **CD40** ligand (CD40L), a 33-kDa type II membrane glycoprotein expressed primarily on activated CD4+ T lymphocytes, is responsible for the helper function of T cells on resting B cells in a non-antigen-dependent, non-major histocompatability complex-restricted fashion. Interaction of CD40L with its receptor **CD40** induces proliferation of and isotype switching in B lymphocytes. Recently we solved the x-ray structure of recombinant soluble CD40L and showed that, similar to other members of the tumor necrosis factor family, CD40L indeed exists as a trimer. We now report that, under normal physiological conditions, CD40L molecules exist as heteromultimeric complexes. These CD40L complexes, made of the full length and smaller fragments of CD40L, are present on the cell surface of T lymphocytes and are capable of interacting with **CD40** molecule. A prominent fragment with a mass of 31 kDa accounts for as much as half of the CD40L on the surface of Jurkat cells. Nterminal sequence data revealed that this fragment lacks the cytoplasmic tail. A minor 18-kDa fragment of CD40L was also characterized which lacks the cytoplasmic tail, transmembrane region, and stalk region of the extracellular domain. The presence of CD40L heteromultimeric variants implies an additional regulation of the functional activity of this ligand complex.

3/7/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10452658 BIOSIS NO.: 199699073803
Crystallographic studies of human **CD40** ligand.
AUTHOR: Karpusas Michael(a); Hsu Yen-Ming(a); Wang Jia-Huai; Garber Ellen (a); Strauch Kathy(a); Thompson Jeff(a); Mullen Colleen(a); Lederman Seth ; Ches Leonard; **Thomas David**(a
AUTHOR ADDRESS: (a)Biogen, Inc., 12 Cambridge Cent., Cambridge, MA 02142** USA
JOURNAL: European Cytokine Network 7 (2):p170 1996
CONFERENCE/MEETING: 6th International Tumor Necrosis Factor Congress Rhodes, Greece May 8-12, 1996
ISSN: 1148-5493
RECORD TYPE: Citation
LANGUAGE: English

3/7/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10103441 BIOSIS NO.: 199698558359
2 A crystal structure of an extracellular fragment of human **CD40** ligand.
AUTHOR: Karpusas Michael(a); Hsu Yen-Ming; Wang Jia-Huai; Thompson Jeff; Lederman Seth; Chess Leonard; **Thomas David**
AUTHOR ADDRESS: (a)Biogen Inc., 12 Cambridge Center, Cambridge, MA 02142** USA
JOURNAL: Structure (London) 3 (10):p1031-1039 1995
ISSN: 0969-2126
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

```
LANGUAGE: English

ABSTRACT: Background: The CD40 ligand (CD40L) is a member of the
  tumor necrosis factor (TNF) family of proteins and is transiently
  expressed on the surface of activated T cells. The binding of CD40L to
  CD40, which is expressed on the surface of B cells, provides a
  critical and unique pathway of cellular activation resulting in antibody
  isotype switching, regulation of apoptosis, and B cell proliferation and
  differentiation. Naturally occurring mutations of CD40L result in the
  clinical hyper-IgM syndrome, characterized by an inability to produce
  immunoglobulins of the IgG, IgA and IgE isotypes. Results: We have
  determined the crystal structure of a soluble extracellular fragment of
  human CD40L to 2 ANG resolution and with an R factor of 21.8%. Although
  the molecule forms a trimer similar to that found for other members of
  the TNF family, such as TNF-alpha and lymphotoxin-alpha, and exhibits a
  similar overall fold, there are considerable differences in several loops
  including those predicted to be involved in CD40 binding.
  Conclusions: The structure suggests that most of the hyper-IgM syndrome
  mutations affect the folding and stability of the molecule rather than
  the CD40-binding site directly. Despite the fact that the hyper-IgM
  syndrome mutations are dispersed in the primary sequence, a large
  fraction of them are clustered in space in the vicinity of a surface
  loop, close to the predicted CD40-binding site.
? s (agonist? or stimulat?)(10n)(cd40 or g28(w)5)(10n)(antibod?)
Processing
          398092  AGONIST?
         2021414  STIMULAT?
           15418  CD40
             217  G28
         5532817  5
             118  G28(W)5
         1735131  ANTIBOD?
      S4     622  (AGONIST? OR STIMULAT?)(10N)(CD40 OR
                  G28(W)5)(10N)(ANTIBOD?)
? rd s4
...examined 50 records  (50)
...examined 50 records  (100)
...examined 50 records  (150)
...examined 50 records  (200)
...examined 50 records  (250)
...examined 50 records  (300)
...examined 50 records  (350)
...examined 50 records  (400)
...examined 50 records  (450)
...examined 50 records  (500)
...examined 50 records  (550)
...examined 50 records  (600)
...completed examining records
      S5     279  RD S4 (unique items)
? s s5 and cd40L
             279  S5
            3948  CD40L
      S6     34  S5 AND CD40L
? rd s6
...completed examining records
      S7     34  RD S6 (unique items)
? s s5 and (cd40L or cd40(w)ligand)
             279  S5
            3948  CD40L
           15418  CD40
          320025  LIGAND
            6912  CD40(W)LIGAND
      S8     106  S5 AND (CD40L OR CD40(W)LIGAND)
? rd s8
```

...examined 50 records (50)
...examined 50 records (100)
...completed examining records
S9 106 RD S8 (unique items)
? t s9/3/all

9/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13764366 BIOSIS NO.: 200200393187
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: Induction of bax.
AUTHOR: Szocinski Jamie L; Khaled Annette R; Hixon Julie; Halverson Douglas ; Funakoshi Satoshi; Fanslow William C; Boyd Ann; Taub Dennis D; Durum Scott K; Siegall Clay B; Longo Dan L; Murphy William J(a)
AUTHOR ADDRESS: (a)SAIC-Frederick, National Cancer Institute at Frederick, Bldg 567, Rm 210, Frederick, MD, 21702**USA E-Mail: murphyw@ncifcrf.gov
JOURNAL: Blood 100 (1):p217-223 July 1, 2002
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13741782 BIOSIS NO.: 200200370603
Activation of antigen presenting cells (APCs) through toll like receptor (TLR) 9 or CD40 reverses tolerance and precipitates autoimmune disease.
AUTHOR: Segal Benjamin Matthew(a); Ichikawa Hiroshi Travis
AUTHOR ADDRESS: (a)Neurology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 605, Rochester, NY, 14642**USA
JOURNAL: FASEB Journal 16 (5):pA1066 March 22, 2002
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of Professional Research Scientists on Experimental Biology New Orleans, Louisiana, USA April 20-24, 2002
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English

9/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13730004 BIOSIS NO.: 200200358825
CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells.
AUTHOR: Hermann Alexander; Schroer Karsten(a); Weber Artur-Aron
AUTHOR ADDRESS: (a)Institut fuer Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universitaet, Moorenstr. 5, D-40225, Duesseldorf**Germany E-Mail: kschroer@uni-duesseldorf.de
JOURNAL: European Journal of Cell Biology 81 (4):p213-221 April, 2002
MEDIUM: print
ISSN: 0171-9335
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13719326 BIOSIS NO.: 200200348147
Use of **CD40 ligand**, a cytokine that binds CD40, to stimulate hybridoma cells.
AUTHOR: Armitage Richard J(a); Fanslow William C; Spriggs Melanie K; Srinivasan Subhashini; Gibson Marylou G
AUTHOR ADDRESS: (a)5133 Eagle Harbor Dr., Bainbridge Island, WA, 98110**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1258 (3):pNo Pagination May 21, 2002
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

9/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13700475 BIOSIS NO.: 200200329296
CD40/**CD40 ligand** interactions in the host defense against disseminated Candida albicans infection: The role of macrophage-derived nitric oxide.
AUTHOR: Netea Mihai G; van der Meer Jos W M; Verschueren Ineke; Kullberg Bart Jan(a)
AUTHOR ADDRESS: (a)Department of Medicine, University Medical Center St. Radboud, 541, 6500 HB, Nijmegen**Netherlands E-Mail: B.Kullberg@AIG.AZN.NL
JOURNAL: European Journal of Immunology 32 (5):p1455-1463 May, 2002
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13612394 BIOSIS NO.: 200200241215
Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma.
AUTHOR: Weng Wen-Kai(a); Wang Changyu; Chu Keting; Levy Ronald(a)
AUTHOR ADDRESS: (a)Medicine/Oncology, Stanford University, Stanford, CA** USA
JOURNAL: Blood 98 (11 Part 1):p466a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

9/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13557719 BIOSIS NO.: 200200186540

Differential responses of Burkitts lymphoma cells to CD40 ligation: Optimal stimulation requires efficient receptor oligomerisation.
AUTHOR: Chapman Rachel S(a); Rickinson Alan B(a); Young Lawrence S(a)
AUTHOR ADDRESS: (a)CRC Institute for Cancer Studies, Birmingham University, Birmingham, West Midlands**UK
JOURNAL: Blood 98 (11 Part 1):p332a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

9/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13440351 BIOSIS NO.: 200200069172
Enforced and prolonged **CD40 ligand** expression triggers autoantibody production in vivo.
AUTHOR: Santos-Argumedo Leopoldo(a); Alvarez-Maya Ikuri; Romero-Ramirez Hector; Flores-Romo Leopoldo
AUTHOR ADDRESS: (a)Department of Molecular Biomedicine, Centro de Investigacion y Estudios Avanzados, I.P.N., cp 07360, Mexico, D.F.** Mexico E-Mail: lesantos@mail.cinvestav.mx
JOURNAL: European Journal of Immunology 31 (12):p3484-3492 December, 2001
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13267128 BIOSIS NO.: 200100474277
Autoreactive CD4+ T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: Preferential recognition of the major phospholipid-binding site.
AUTHOR: Arai Takahide; Yoshida Kazue; Kaburaki Junichi; Inoko Hidetoshi; Ikeda Yasuo; Kawakami Yutaka; Kuwana Masataka(a)
AUTHOR ADDRESS: (a)Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582: kuwanam@sc.itc.keio.ac.jp**Japan
JOURNAL: Blood 98 (6):p1889-1896 September 15, 2001
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13202980 BIOSIS NO.: 200100410129
Pathways for self-tolerance and the treatment of autoimmune diseases.
AUTHOR: Goodnow Christopher C(a)
AUTHOR ADDRESS: (a)Australian Cancer Research Foundation, Genetics

Laboratory, Medical Genome Centre, John Curtin School of Medical Research, Australian National University, Canberra, 2601: chris.goodnow@anu.edu.au**Australia
JOURNAL: Lancet (North American Edition) 357 (9274):p2115-2121 30 June, 2001
MEDIUM: print
ISSN: 0099-5355
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13118157 BIOSIS NO.: 200100325306
The in vitro proliferation of murine lymphocytes to mercuric chloride is restricted to mature T cells and is interleukin 1 dependent.
AUTHOR: Pollard K Michael(a); Landberg Goran P
AUTHOR ADDRESS: (a)W.M. Keck Autoimmune Disease Center, Department of Molecular and Experimental Medicine, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037: mpollard@scripps.edu**USA
JOURNAL: International Immunopharmacology 1 (3):p581-593 March, 2001
MEDIUM: print
ISSN: 1567-5769
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13071518 BIOSIS NO.: 200100278667
The inducible costimulatory (ICOS) molecule is critical for antibody class switching.
AUTHOR: McAdam Alexander John(a); Greenwald Rebecca(a); Levin Michele(a); Ling Vincent; Chernova Tatyana; Malenkovich Nelly; Freeman Gordon; Sharpe Arlene(a)
AUTHOR ADDRESS: (a)Brigham and Womens Hospital, 221 Longwood Ave., LMRC 5th Floor, Boston, MA, 02115**USA
JOURNAL: FASEB Journal 15 (4):pA345 March 7, 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13060592 BIOSIS NO.: 200100267741
Regulation of iNOS expression and myocardial cell death: Mechanisms of allograft survival with **CD40L** deficiency.
AUTHOR: Shimizu Koichi(a); Rabkin Elena(a); Schoenbeck Uwe(a); Libby Peter

(a); Mitchell Richard N(a)
AUTHOR ADDRESS: (a)Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115**USA
JOURNAL: FASEB Journal 15 (4):pA670 March 7, 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13013882 BIOSIS NO.: 200100221031
B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation.
AUTHOR: Rush James S; Hodgkin Philip D(a)
AUTHOR ADDRESS: (a)Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW, 2042: p.hodgkin@centenary.usyd.edu.au**Australia
JOURNAL: European Journal of Immunology 31 (4):p1150-1159 April, 2001
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12806263 BIOSIS NO.: 200100013412
Differential effects of CD40 stimulation on normal and neoplastic cell growth.
AUTHOR: Ziebold Jamie L; Hixon Julie; Boyd Ann; Murphy William J(a)
AUTHOR ADDRESS: (a)SAIC-Frederick, NCI-FCRDC, Building 567, Room 210, Frederick, MD, 21702: murphyw@mail.ncifcrf.gov**USA
JOURNAL: Archivum Immunologiae et Therapiae Experimentalis 48 (4):p225-233 2000
MEDIUM: print
ISSN: 0004-069X
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12741467 BIOSIS NO.: 200000495090
Osteopontin augments CD3-mediated interferon-gamma and **CD40 ligand** expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells.
AUTHOR: O'Regan Anthony W; Hayden Jason M; Berman Jeffrey S(a)
AUTHOR ADDRESS: (a)Pulmonary Center, Boston University School of Medicine, 715 Albany Street, Boston, MA, 02118**USA

JOURNAL: Journal of Leukocyte Biology 68 (4):p495-502 October, 2000
MEDIUM: print
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12678872 BIOSIS NO.: 200000432374
Increased expression of **CD40 ligand** in activated CD4+ T lymphocytes of systemic sclerosis patients.
AUTHOR: Valentini Gabriele(a); Romano Maria Fiammetta; Naclerio Caterina; Bisogni Rita; Lamberti Annalisa; Turco Maria Caterina; Venuta Salvatore
AUTHOR ADDRESS: (a)Istituto di Clinica Medica e Reumatologia, II Universita di Napoli, Via Pansini, 5, 80131, Napoli**Italy
JOURNAL: Journal of Autoimmunity 15 (1):p61-66 August, 2000
MEDIUM: print
ISSN: 0896-8411
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12604864 BIOSIS NO.: 200000358366
Agonistic properties and in vivo antitumor activity of the anti-**CD40 antibody** SGN-14.
AUTHOR: Francisco Joseph A; Donaldson Karen L; Chace Dana; Siegall Clay B; Wahl Alan F(a)
AUTHOR ADDRESS: (a)Department of Biochemistry, Seattle Genetics, Inc., 22215 26th Avenue SE, Bothell, WA, 98021**USA
JOURNAL: Cancer Research 60 (12):p3225-3231 June 15, 2000
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/19 (Item 19 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12574085 BIOSIS NO.: 200000327587
An increased number of CD40-high monocytes in patients with Crohn's disease.
AUTHOR: Sawada-Hase Naoko; Kiyohara Tatsuya(a); Miyagawa Jun-ichiro; Ueyama Harumi; Nishibayashi Hiroyuki; Murayama Yoko; Kashihara Takeshi; Nakahara Masanori; Miyazaki Yoshiji; Kanayama Shuji; Nezu Riichiro; Shinomura Yasuhisa; Matsuzawa Yuji
AUTHOR ADDRESS: (a)Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, 2-2 B-5 Yamadaoka, Suita, Osaka, 565-0871**Japan
JOURNAL: American Journal of Gastroenterology 95 (6):p1516-1523 June, 2000

MEDIUM: print
ISSN: 0002-9270
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12571721 BIOSIS NO.: 200000325223
CD40-**CD40 ligand** interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes.
AUTHOR: Moodycliffe Angus M; Shreedhar Vijay; Ullrich Stephen E; Walterscheid Jeffrey; Bucana Corazon; Kripke Margaret L; Flores-Romo Leopoldo(a)
AUTHOR ADDRESS: (a)Inq.: Ms. Sue Adams, Dept. of Immunology-178, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030**USA
JOURNAL: Journal of Experimental Medicine 191 (11):p2011-2020 June 5, 2000
MEDIUM: print
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/21 (Item 21 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12464970 BIOSIS NO.: 200000218472
Depressed **CD40 ligand** expression contributes to reduced gamma interferon production in human tuberculosis.
AUTHOR: Samten Buka; Thomas Elaine K; Gong Jianhua; Barnes Peter F(a)
AUTHOR ADDRESS: (a)Center for Pulmonary and Infectious Disease Control, University of Texas Health Center at Tyler, 11937 U.S. Highway 271, Tyler, TX, 75708-3154**USA
JOURNAL: Infection and Immunity 68 (5):p3002-3006 May, 2000
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12440849 BIOSIS NO.: 200000194351
Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth.
AUTHOR: Li Li; Zhang Xin; Kovacic Sharlotte; Long Andrew J; Bourque Karen; Wood Clive R; Choi Yong Sung(a)
AUTHOR ADDRESS: (a)Laboratory of Cellular Immunology, Alton Ochsner Medical Foundation, 1516 Jefferson Hwy., New Orleans, LA, 70121**USA
JOURNAL: Journal of Experimental Medicine 191 (6):p1077-1083 March 20, 2000
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12349382 BIOSIS NO.: 200000102884
CD40 signals apoptosis through FAN-regulated activation of the sphingomyelin-ceramide pathway.
AUTHOR: Segui Bruno; Andrieu-Abadie Nathalie; Adam-Klages Sabine; Meilhac Olivier; Kreder Dirk; Garcia Virginie; Bruno Alain P; Jaffrezou Jean-Pierre; Salvayre Robert; Kroenke Martin; Lèvade Thierry(a)
AUTHOR ADDRESS: (a)Laboratoire de Biochimie, INSERM U466, Institut Louis Bugnard, Centre Hospitalier Universitaire Rangueil, 1 Avenue Jean Poulhes, Batiment L3, F-31403, Toulouse Cedex 4**France
JOURNAL: Journal of Biological Chemistry 274 (52):p37251-37258 Dec. 24, 1999
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/24 (Item 24 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12215880 BIOSIS NO.: 199900510729
Antibody production in autoimmune BXSB mice. I. **CD40L**-expressing B cells need fewer signals for polyclonal antibody synthesis.
AUTHOR: Blossom S; Gilbert K M(a)
AUTHOR ADDRESS: (a)University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR, 72205**USA
JOURNAL: Clinical and Experimental Immunology 118 (1):p147-153 Oct., 1999
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/25 (Item 25 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12215818 BIOSIS NO.: 199900510667
Staphylococcus aureus Cowan strain 1 activation of B-chronic lymphocytic leukaemia cells augments the response to CD40 stimulation.
AUTHOR: Soderberg O(a); Thunberg U; Weigelt C; Christiansen I; Totterman T H; Carlsson M; Sallstrom J; Nilsson K
AUTHOR ADDRESS: (a)Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Dr Roberto Frias s/n, 4200, Porto** Portugal
JOURNAL: Scandinavian Journal of Immunology 50 (4):p363-370 Oct., 1999
ISSN: 0300-9475
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/26 (Item 26 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12203394 BIOSIS NO.: 199900498243
Activation sensitizes human memory B cells to B-cell receptor-induced apoptosis.
AUTHOR: Berard M; Casamayor-Palleja M; Billian G; Bella C; Mondiere P; Defrance T(a)
AUTHOR ADDRESS: (a)INSERM U 404, Avenue Tony Garnier, 69365, Lyon, Cedex 07 **France
JOURNAL: Immunology 98 (1):p47-54 Sept., 1999
ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/27 (Item 27 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12187499 BIOSIS NO.: 199900482348
CD40-**CD40 ligand** interactions augment survival of normal mice, but not **CD40 ligand** knockout mice, challenged orally with Salmonella dublin.
AUTHOR: Marriott Ian; Thomas Elaine K; Bost Kenneth L(a)
AUTHOR ADDRESS: (a)Department of Biology, University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC, 28223**USA
JOURNAL: Infection and Immunity 67 (10):p5253-5257 Oct., 1999
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/28 (Item 28 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11979865 BIOSIS NO.: 199900233178
Inhibition of human breast carcinoma growth by a soluble recombinant human **CD40 ligand**.
AUTHOR: Hirano Akio; Longo Dan L; Taub Dennis D; Ferris Douglas K; Young Lawrence S; Eliopoulos Arisitides G; Agathanggelou Angelo; Cullen Nicky; Macartney James; Fanslow William C; Murphy William J(a)
AUTHOR ADDRESS: (a)SAIC-Frederick, Bldg 567, Room 210, Frederick, MD**USA
JOURNAL: Blood 93 (9):p2999-3007 May 1, 1999
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/29 (Item 29 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11979280 BIOSIS NO.: 199900232593
CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation.

AUTHOR: Chaussabel Damien; Jacobs Frederique; De Jonge Jan; De Veerman Marijke; Carlier Yves; Thielemans Kris; Goldman Michel; Vray Bernard(a)
AUTHOR ADDRESS: (a)Laboratoire d'Immunologie Experimentale, Faculte de Medecine, Universite Libre de Bruxelles, rou**Belgium
JOURNAL: Infection and Immunity 67 (4):p1929-1934 April, 1999
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

9/3/30 (Item 30 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11648220 BIOSIS NO.: 199800429951
Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-**CD40L**/B7-1 monoclonal antibodies.
AUTHOR: Seko Yoshinori(a); Takahashi Naoyuki; Azuma Miyuki; Yagita Hideo; Okumura Ko; Yazaki Yoshio
AUTHOR ADDRESS: (a)Third Dep. Intern. Med., Fac. Med., Univ. Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113**Japan
JOURNAL: Circulation Research 83 (4):p463-469 Aug. 24, 1998
ISSN: 0009-7330
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/31 (Item 31 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11624085 BIOSIS NO.: 199800406331
Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis.
AUTHOR: Jakobson Eva(a); Jonsson Gun; Bjorck Pia; Paulie Staffan
AUTHOR ADDRESS: (a)Dep. Immunology, Stockholm Univ., S-106 91 Stocholm** Sweden
JOURNAL: International Journal of Cancer 77 (6):p849-853 Sept. 11, 1998
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/32 (Item 32 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11516369 BIOSIS NO.: 199800297701
Expression and function of CD40 in rheumatoid arthritis synovium.
AUTHOR: Sekine Chiyoko; Yagita Hideo; Miyasaka Nobuyuki; Okumura K(a)
AUTHOR ADDRESS: (a)Dep. Immunol., Juntendo Univ. School Med., 2-1-1 Hongo, Bunkyo-ku, Tokyo 113**Japan
JOURNAL: Journal of Rheumatology 25 (6):p1048-1053 June, 1998
ISSN: 0315-162X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/33 (Item 33 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11296955 BIOSIS NO.: 199800078287
Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-variant kappaB.
AUTHOR: Yoshimoto Takayuki(a); Nagase Hisashi; Ishida Takaomi; Inoue Jun-Ichiro; Nariuchi Hideo
AUTHOR ADDRESS: (a)Dep. Allergol., Inst. Med. Sci., Univ. Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108**Japan
JOURNAL: European Journal of Immunology 27 (12):p3461-3470 Dec., 1997
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/34 (Item 34 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11296938 BIOSIS NO.: 199800078270
CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells.
AUTHOR: Koppi Thelma A(a); Tough-Bement Teresa; Lewinsohn David M; Lynch David H; Alderson Mark R
AUTHOR ADDRESS: (a)Dep. Immunol., Corixa Corp., 1124 Columbia St., Suite 464, Seattle, WA 98104**USA
JOURNAL: European Journal of Immunology 27 (12):p3161-3165 Dec., 1997
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/35 (Item 35 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11037864 BIOSIS NO.: 199799659009
Modulation of soluble **CD40 ligand** bioactivity with anti-CD40 antibodies.
AUTHOR: Schwabe Robert F; Hess Sigrun; Johnson Judith P; Engelmann Hartmut (a)
AUTHOR ADDRESS: (a)Inst. Immunol., Goethestr. 31, 80336 Muenchen**Germany
JOURNAL: Hybridoma 16 (3):p217-226 1997
ISSN: 0272-457X
RECORD TYPE: Abstract
LANGUAGE: English

9/3/36 (Item 36 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10990346 BIOSIS NO.: 199799611491
CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells.
AUTHOR: Jeannin Pascale; Delneste Yves; Lecoanet-Henchoz Sybille; Gauchat Jean-Francois; Ellis Jonathan; Bonnefoy Jean-Yves(a)
AUTHOR ADDRESS: (a)Geneva Biomedical Res. Inst., Glaxo Wellcome Res. Development, Immunol. Dep., 14 Chemin des Aulx**Switzerland
JOURNAL: Journal of Biological Chemistry 272 (25):p15613-15619 1997

ISSN: 0021-9258
RECORD TYPE: Abstract
LANGUAGE: English

9/3/37 (Item 37 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10984118 BIOSIS NO.: 199799605263
Interleukin-13 in combination with **CD40 ligand** potently inhibits apoptosis in human B lymphocytes: Upregulation of Bcl-xL and McL-1.
AUTHOR: Lomo Jon(a); Blomhoff Heidi Kiil; Jacobsen Sten Eirik; Krajewski Stanislaw; Reed John C; Smeland Erlend B
AUTHOR ADDRESS: (a)Dep. Immunology, Inst. Cancer Res., The Norwegian Radium Hosp., N-0310 Oslo**Norway
JOURNAL: Blood 89 (12):p4415-4424 1997
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

9/3/38 (Item 38 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10922564 BIOSIS NO.: 199799543709
Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-**CD40 antibodies**, and the soluble **CD40 ligand**.
AUTHOR: Buske Christian(a); Gogowski Gerald; Schreiber Karin; Rave-Fraenk Margret; Hiddemann Wolfgang; Woermann Bernhard
AUTHOR ADDRESS: (a)Dep. Internal Med., Div. Hematol./Oncol., Univ. Hosp., Robert-Koch-Str. 40, 37075 Goettingen**Germany
JOURNAL: Experimental Hematology (Charlottesville) 25 (4):p329-337 1997
ISSN: 0301-472X
RECORD TYPE: Abstract
LANGUAGE: English

9/3/39 (Item 39 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10851739 BIOSIS NO.: 199799472884
Induction and differential regulation of bee venom phospholipase A-2-specific human IgE and IgG-4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells.
AUTHOR: Akdis Cezmi A(a); Blesken Thorsten; Akdis Mubeccel; Alkan Sefik S; Wuthrich Brunello; Heusser Christoph H; Blaser Kurt
AUTHOR ADDRESS: (a)Swiss Inst. Allergy Asthma Res., Obere Strasse 22, CH-7270 Davos Platz**Switzerland
JOURNAL: Journal of Allergy and Clinical Immunology 99 (3):p345-353 1997
ISSN: 0091-6749
RECORD TYPE: Abstract
LANGUAGE: English

9/3/40 (Item 40 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10803314 BIOSIS NO.: 199799424459

CD40-**CD40L** interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells.
AUTHOR: Pericle Federica(a); Epling-Burnette P K; Podack Eckhard R; Wei Sheng; Deju Julie Y
AUTHOR ADDRESS: (a)Exp. Immunol. Branch, NCI, NIH, Build. 10, Room 4B-17, Bethesda, MD 20892**USA
JOURNAL: Journal of Leukocyte Biology 61 (2):p201-208 1997
ISSN: 0741-5400
RECORD TYPE: Abstract
LANGUAGE: English

9/3/41 (Item 41 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10731391 BIOSIS NO.: 199799352536
Inhibition of aggressive histology human B cell lymphoma growth by **CD40 stimulation** in vivo: A comparison of a **CD40 antibody** and a recombinant soluble **CD40 ligand** (srCD40L).
AUTHOR: Murphy W J(a); Asai O; Hirano A; Funakoshi S; Fanslow W C; Longo D L
AUTHOR ADDRESS: (a)LLB, DBS, NCI, Frederick, MD**USA
JOURNAL: Blood 88 (10 SUPPL. 1 PART 1-2):p89A 1996
CONFERENCE/MEETING: Thirty-eighth Annual Meeting of the American Society of Hematology Orlando, Florida, USA December 6-10, 1996
ISSN: 0006-4971
RECORD TYPE: Citation
LANGUAGE: English

9/3/42 (Item 42 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10714409 BIOSIS NO.: 199799335554
Activated T hybridomas induce upregulation of B7-1 on bystander B lymphoma cells by a contact-dependent interaction utilizing **CD40 ligand**.
AUTHOR: Jones Keith W(a); Hackett Charles J
AUTHOR ADDRESS: (a)Spectra Biomed. Inc., Dep. Molecular Genetics, 4040 Campbell Ave., Menlo Park, CA 94025**USA
JOURNAL: Cellular Immunology 174 (1):p42-53 1996
ISSN: 0008-8749
RECORD TYPE: Abstract
LANGUAGE: English

9/3/43 (Item 43 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10664771 BIOSIS NO.: 199799285916
Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen.
AUTHOR: Planken E V(a); Dijkstra N H; Bakkus M; Willemze R; Kluin-Nelemans J C
AUTHOR ADDRESS: (a)Dep. Haematology, Bldg 1, C2-R, Rijnsburgerweg 10, 2333 AA Leiden**Netherlands
JOURNAL: British Journal of Haematology 95 (2):p319-326 1996
ISSN: 0007-1048
RECORD TYPE: Abstract
LANGUAGE: English

9/3/44 (Item 44 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10626524 BIOSIS NO.: 199699247669
Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: Role for inhibition of an early response gene, Berg36.
AUTHOR: Ning Zhi-Qiang; Norton John D; Li Jin; Murphy John J(a)
AUTHOR ADDRESS: (a)Infection Immunity Res. Group, Div. Life Sci., King's Coll. London, London W8 7AH**UK
JOURNAL: European Journal of Immunology 26 (10):p2356-2363 1996
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/45 (Item 45 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10461023 BIOSIS NO.: 199699082168
Human dendritic cells activate T lymphocytes via a CD40: **CD40 ligand**-dependent pathway.
AUTHOR: McLellan Alexander D; Sorg Rudiger V; Williams Lisa A; Hart Derek N J(a)
AUTHOR ADDRESS: (a)Haematol./Immunol. Res. Group, Christchurch Hosp., P.O. Box 151, Christchurch**New Zealand
JOURNAL: European Journal of Immunology 26 (6):p1204-1210 1996
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/46 (Item 46 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10429050 BIOSIS NO.: 199699050195
BCL-6 expression during B-cell activation.
AUTHOR: Allman David; Jain Ashish; Dent Alex; Maile Randal R; Selvaggi Thomas; Kehry Marilyn R; Staudt Louis M(a)
AUTHOR ADDRESS: (a)Metabolism Branch, Natl. Cancer Inst., Natl. Inst. Health, Build. 10, Room 4N114, 9000 Rockville**USA
JOURNAL: Blood 87 (12):p5257-5268 1996
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/47 (Item 47 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10374181 BIOSIS NO.: 199698829099
CD40-mediated **stimulation** contributes to lymphocyte proliferation, **antibody** production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production.

AUTHOR: Lu Pin; Urban Joseph F; Di Zhou Xia; Chen S-J; Madden Kathleen; Moorman Mark; Nguyen Huong; Morris Suzanne C; Finkelman Fred D; Gause William C(a)
AUTHOR ADDRESS: (a)Dep. Microbiol., B3106, USUHS, 4301 Jones Bridge Road, Bethesda, MD 20814-4799**USA
JOURNAL: Journal of Immunology 156 (9):p3327-3333 1996
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/48 (Item 48 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10339644 BIOSIS NO.: 199698794562
CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation.
AUTHOR: Pellat-Deceunynck Catherine(a); Amiot Martine; Robillard Nelly; Wijdenes John; Bataille Regis
AUTHOR ADDRESS: (a)Lab. d'Oncogenese Immunohematol., Inst. Biol., 9, quai Moncousu, 44035 Nantes Cedex 01**France
JOURNAL: Cancer Research 56 (8):p1909-1916 1996
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/49 (Item 49 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10331405 BIOSIS NO.: 199698786323
CD40 expression by human peripheral blood eosinophils.
AUTHOR: Ohkawara Yuichi; Lim Kaiser G; Xing Zhou; Gilbetic Marija; Nakano Koichi; Dolovich Jerry; Croitoru Kenneth; Weller Peter F; Jordana Manel (a)
AUTHOR ADDRESS: (a)Dep. Pathol., Room 4H 21 McMaster Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5**Canada
JOURNAL: Journal of Clinical Investigation 97 (7):p1761-1766 1996
ISSN: 0021-9738
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/50 (Item 50 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10218597 BIOSIS NO.: 199698673515
B cell-B cell interaction through intercellular adhesion molecule-1 and lymphocyte functional antigen-1 regulates immunoglobulin E synthesis by B cells **stimulated** with interleukin-4 and anti-**CD40** **antibody**.
AUTHOR: Katada Yoshinori; Tanaka Toshio; Ochi Hiroshi; Aitani Masakazu; Yokota Akira; Kikutani Hitoshi; Suemura Masaki; Kishomoto Tadamitsu(a)
AUTHOR ADDRESS: (a)Dep. Med. III, Osaka University Medical School 2-2 Yamada-oka, Suita City, Osaka 565**Japan
JOURNAL: European Journal of Immunology 26 (1):p192-200 1996
ISSN: 0014-2980
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

9/3/51 (Item 51 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10194488 BIOSIS NO.: 199698649406
CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype.
AUTHOR: Galibert Laurent(a); Burdin Nicolas; De Saint-Vis Blandine; Garrone Pierre; Van Kooten Cees; Banchereau Jacques; Rousset Francoise
AUTHOR ADDRESS: (a)Lab. Immunol. Res., Schering-Plough, 27 Chemin des Peupliers, B.P. 11, 69571 Dardilly Cedex**France
JOURNAL: Journal of Experimental Medicine 183 (1):p77-85 1996
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/52 (Item 52 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10178632 BIOSIS NO.: 199698633550
CD40 ligand-transduced co-stimulation of T cells in the development of helper function.
AUTHOR: Van Essen Dominic; Kikutani Hitoshi; Gray David(a)
AUTHOR ADDRESS: (a)Dep. Immunol., Royal Postgraduate Med. Sch., Hammersmith Hosp., Du Cane Road, London W12 0NN**UK
JOURNAL: Nature (London) 378 (6557):p620-623 1995
ISSN: 0028-0836
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/53 (Item 53 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10139370 BIOSIS NO.: 199698594288
CD40 cross-linking inhibits specific antibody production by human B cells.
AUTHOR: Callard Robin E(a); Herbert Joan; Smith Susan H; Armitage Richard J ; Costelloe Kathy E
AUTHOR ADDRESS: (a)Cellular Immunol. Unit, Inst. Child Health, 30 Guilford Street, London WC1N 1EH**UK
JOURNAL: International Immunology 7 (11):p1809-1815 1995
ISSN: 0953-8178
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/54 (Item 54 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09997888 BIOSIS NO.: 199598452806
Regulation of murine B cell growth and differentiation by CD30 ligand.
AUTHOR: Shanebeck Kurt D; Maliszewski Charles R; Kennedy Mary K; Picha Kathleen S; Smith Craig A; Goodwin Ray G; Grabstein Kenneth H(a)

AUTHOR ADDRESS: (a)Corixa Corportion, 1124 Columbia St., Suite 464, Seattle, WA 98104**USA
JOURNAL: European Journal of Immunology 25 (8):p2147-2153 1995
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/55 (Item 55 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09941951 BIOSIS NO.: 199598396869
Modulation of purified soluble human **CD40 ligand (CD40L)** activity by **agonistic** and antagonistic monoclonal **antibodies**.

BOOK TITLE: The 9th International Congress of Immunology
AUTHOR: Armitage R J; MacDuff B M; Boiani N E; Gibson M G; Morris A E; Dower S K; Fanslow W C
BOOK AUTHOR/EDITOR: 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY
AUTHOR ADDRESS: Immunex Res. Dev. Corp., Seattle, WA**USA
p332 1995
BOOK PUBLISHER: 9th International Congress of Immunology, San Francisco, California, USA
CONFERENCE/MEETING: Meeting Sponsored by the American Association of Immunologists and the International Union of Immunological Societies San Francisco, California, USA July 23-29, 1995
RECORD TYPE: Citation
LANGUAGE: English

9/3/56 (Item 56 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09905119 BIOSIS NO.: 199598360037
Activation of thymic B cells by signals of CD40 molecules plus interleukin-10.
AUTHOR: Inaba Muneo; Inaba Kayo; Fukuba Yoh; Mori Shin-Ichiro; Haruna Hiroki; Doi Hiroshi; Adachi Yasushi; Iwai Hiroshi; Hosaka Naoki; Hisha Hiroko; Yagita Hideo; Ikehara Susumu(a)
AUTHOR ADDRESS: (a)First Dep. Pathol., Kansai Med. Univ., 10-15 Fumizono-cho, Moriguchi City, Osaka 570**Japan
JOURNAL: European Journal of Immunology 25 (5):p1244-1248 1995
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/57 (Item 57 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09712339 BIOSIS NO.: 199598167257
Induction of the transcription factors NF-kappa-B, AP-1 and NF-AT during B cell stimulation through the CD40 receptor.
AUTHOR: Francis Delicia A; Karras James G; Ke Xiao-Yan; Sen Ranjan; Rothstein Thomas L(a)
AUTHOR ADDRESS: (a)Room E-501, Boston Univ. Med. Center, 88 East Newton St., Boston, MA 02118**USA
JOURNAL: International Immunology 7 (2):p151-161 1995
ISSN: 0953-8178

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/58 (Item 58 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09550939 BIOSIS NO.: 199598005857
Antibodies to distinct epitopes on the **CD40** molecule co-operate in **stimulation** and can be used for the detection of soluble **CD40**.
AUTHOR: Bjorck P(a); Braesch-Andersen S; Paulie S
AUTHOR ADDRESS: (a)Dep. Immunol., Stockholm Univ., S-106 91 Stockholm** Sweden
JOURNAL: Immunology 83 (3):p430-437 1994
ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/59 (Item 59 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09441306 BIOSIS NO.: 199497449676
Decreased expression of the ligand for CD40 in newborn lymphocytes.
AUTHOR: Fuleihan Ramsay(a); Ahern Deborah; Geha Raif S
AUTHOR ADDRESS: (a)Div. Immunol., Enders 8, Children's Hosp., 300 Longwood Ave., Boston, MA 02115**USA
JOURNAL: European Journal of Immunology 24 (8):p1925-1928 1994
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/60 (Item 60 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09300364 BIOSIS NO.: 199497308734
Inhibition of human B-cell lymphoma growth by CD40 stimulation.
AUTHOR: Funakoshi Satoshi(a); Longo Dan L; Beckwith Margaret; Conley Denise K; Tsarfaty Galia; Tsarfaty Ilan; Armitage Richard J; Fanslow William C; Sprigga Melanie K; Murphy William J
AUTHOR ADDRESS: (a)Lab. Leukocyte Biol., Biological Response Modifiers Program, NCI-FCRDC, Build. 567, Room 141, Fr**USA
JOURNAL: Blood 83 (10):p2787-2794 1994
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/61 (Item 61 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09182659 BIOSIS NO.: 199497191029
Activated CD4+ T cells induce CD40-dependent proliferation of human B cell precursors.

AUTHOR: Renard Nathalie(a); Duvert Valerie; Blanchard Dominique; Banchereau Jacques; Saeland Sem
AUTHOR ADDRESS: (a)Schering-Plough, Lab. Immunological Res., 27 chemin des Peupliers, 69571 Dardilly**France
JOURNAL: Journal of Immunology 152 (4):p1693-1701 1994
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/62 (Item 62 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09132495 BIOSIS NO.: 199497140865
CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.
AUTHOR: Farrington Mary(a); Grosmaire Laura S; Nonoyama Shigeaki; Fischer Susanna H; Hollenbaugh Diane; Ledbetter Jeffrey A; Noelle Randolph J; Aruffo Alejandro; Ochs Hans D
AUTHOR ADDRESS: (a)Dep. Pediatr., Univ. Washington Med. Sch., Seattle, WA 98195**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 91 (3):p1099-1103 1994
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/63 (Item 63 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08960754 BIOSIS NO.: 199396112255
B cell activation via **CD40** is required for specific **antibody** production by antigen-**stimulated** human B cells.
AUTHOR: Nonoyama Shigeaki(a); Hollenbaugh Diane; Aruffo Alejandro; Ledbetter Jeffrey A; Ochs Hans D
AUTHOR ADDRESS: (a)Dep. Pediatrics, RD-20, Sch. Med., University Washington, Seattle, WA 98195**USA
JOURNAL: Journal of Experimental Medicine 178 (3):p1097-1102 1993
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/64 (Item 64 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08355915 BIOSIS NO.: 000094096438
IDENTIFICATION OF A SOURCE OF BIOLOGICALLY ACTIVE **CD40 LIGAND**
AUTHOR: ARMITAGE R J; SATO T A; MACDUFF B M; CLIFFORD K N; ALPERT A R; SMITH C A; FANSLOW W C
AUTHOR ADDRESS: DEP. IMMUNOL., IMMUNEX RES. DEV. CORPORATION, 51 UNIVERSITY ST., SEATTLE, WASHINGTON 98101.
JOURNAL: EUR J IMMUNOL 22 (8). 1992. 2071-2076. 1992
FULL JOURNAL NAME: European Journal of Immunology
CODEN: EJIMA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

9/3/65 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11665089 EMBASE No: 2002237167
3rd International Symposium on Genetic Anticancer Agents
Wysocki P.J.; Mackiewicz-Wysocka M.
Dr. P.J. Wysocki, Department of Cancer Immunology, USOMS, GreatPoland Cancer Center, Garbary Street 15, 61-866 Poznan Poland
AUTHOR EMAIL: pwysocki@plusnet.pl
Expert Opinion on Biological Therapy (EXPERT OPIN. BIOL. THER.) (United Kingdom) 2002, 2/5 (565-568)
CODEN: EOBTA ISSN: 1471-2598
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

9/3/66 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

11639282 EMBASE No: 2002211352
CD154-dependent priming of diabetogenic CD4SUP+ T cells dissociated from activation of antigen-presenting cells
Amrani A.; Serra P.; Yamanouchi J.; Han B.; Thiessen S.; Verdaguer J.; Santamaria P.
P. Santamaria, Julia McFarlane Diabetes Res. Center, University of Calgary, Faculty of Medicine, 3330 Hospital Drive NW, Calgary, Alta. T2N 4N1 Canada
AUTHOR EMAIL: psantama@ucalgary.ca
Immunity (IMMUNITY) (United States) 2002, 16/5 (719-732)
CODEN: IUNIE ISSN: 1074-7613
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 67

9/3/67 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

11617811 EMBASE No: 2002189470
CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB
O'Sullivan B.J.; Thomas R.
Dr. R. Thomas, Ctr. for Immunology/Cancer Research, University of Queensland, Princess Alexandra Hospital, Ipswich Road, Brisbane, QLD 4102 Australia
AUTHOR EMAIL: rthomas@medicine.pa.uq.edu.au
Journal of Immunology (J. IMMUNOL.) (United States) 01 JUN 2002, 168/11 (5491-5498)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

9/3/68 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

11600847 EMBASE No: 2002172884

Tuning tumor-specific T-cell activation: A matter of costimulation?
Abken H.; Hombach A.; Heuser C.; Kronfeld K.; Seliger B.
H. Abken, Tumorgenetik, Klinik I fur Innere Medizin, Universitat zu Koln, D-50931 Koln Germany
AUTHOR EMAIL: hinrich.abken@medizin.uni-koeln.de;
Trends in Immunology (TRENDS IMMUNOL.) (United Kingdom) 01 MAY 2002, 23/5 (240-245)
CODEN: TIRMA ISSN: 1471-4906
PUBLISHER ITEM IDENTIFIER: S1471490602021804
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 54

9/3/69 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE

11461143 EMBASE No: 2002029250
CD40/154 blockade and rejection of islet allografts in the streptozotocin and autoimmune diabetic rat
Kover K.L.; Geng Z.; Hess D.; Benjamin C.; Moore W.V.
Dr. W.V. Moore, Children's Mercy Hospital, Univ. of Kansas Missouri-Kansay City, Section of Pediatric Endocrinology, 2401 Gilham Rd., Kansas City, MO 64108 United States
AUTHOR EMAIL: wmoore@aol.com
Pediatric Diabetes (PEDIATR. DIABETES) (Denmark) 2001, 2/4 (178-183)
CODEN: PDEIB ISSN: 1399-543X
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 24

9/3/70 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE

11432931 EMBASE No: 2002005113
Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates
Montgomery S.P.; Hale D.A.; Hirshberg B.; Harlan D.M.; Kirk A.D.
Dr. D.A. Hale, NIH/Navy Transplant/Autoimmun. Br., N. Inst. Diabet./Digest./Kidney Dis., 10 Center Drive, Bethesda, MD 20892 United States
AUTHOR EMAIL: douglash@intra.niddk.nih.gov
Immunological Reviews (IMMUNOL. REV.) (Denmark) 2001, 183/- (214-222)
CODEN: IMRED ISSN: 0105-2896
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 43

9/3/71 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE

11231428 EMBASE No: 2001248635
T-cell immunity against tumors, a delicate balancing act involving dendritic cells
Melief C.J.M.
C.J.M. Melief, Department of Immunohematology, University Hospital, PO box 9600, 2300 RC Leiden Netherlands
Pathologie Biologie (PATHOL. BIOL.) (France) 2001, 49/6 (498-499)
CODEN: PTBIA ISSN: 0369-8114

DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH; FRENCH
NUMBER OF REFERENCES: 5

9/3/72 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE

11121908 EMBASE No: 2001137461
Increased expression of **CD40 ligand** in activated CD4SUP+ T lymphocytes of systemic sclerosis patients
Valentini G.; Romano M.F.; Naclerio C.; Bisogni R.; Lamberti A.; Turco M.C.; Venuta S.
Prof. G. Valentini, Ist. di Clinica Medica Reumatologia, II Universita di Napoli, Via Pansini, 5, 80131 Napoli Italy
AUTHOR EMAIL: reumasun@mbox.netlab.it
Journal of Autoimmunity (J. AUTOIMMUN.) (United Kingdom) 2000, 15/1 (61-66)
CODEN: JOAUE ISSN: 0896-8411
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33

9/3/73 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE

11117336 EMBASE No: 2001140203
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation
Hixon J.A.; Blazar B.R.; Anver M.R.; Wiltrout R.H.; Murphy W.F.
W.J. Murphy, SAIC-Frederick, NCI-FCRDC, Bldg. 567, Frederick, MD 21702 United States
AUTHOR EMAIL: murphyw@mail.ncifcrf.gov
Biology of Blood and Marrow Transplantation (BIOL. BLOOD MARROW TRANSPLANT.) (United States) 2001, 7/3 (136-143)
CODEN: BBMTF ISSN: 1083-8791
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 20

9/3/74 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE

07675635 EMBASE No: 1999150693
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
Kuniyoshi J.S.; Kuniyoshi C.J.; Lim A.M.; Wang F.Y.; Bade E.R.; Lau R.; Thomas E.K.; Weber J.S.
J.S. Kuniyoshi, Department of Molecular Microbiology, Univ. of S. California Sch. of Med., Los Angeles, CA 90033 United States
Cellular Immunology (CELL. IMMUNOL.) (United States) 10 APR 1999, 193/1 (48-58)
CODEN: CLIMB ISSN: 0008-8749
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 47

9/3/75 (Item 11 from file: 73)

DIALOG(R)File 73:EMBASE

06804938 EMBASE No: 1997087423
Induction and differential regulation of bee venom phospholipase Ainf 2-specific human IgE and IgGinf 4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells
Akdis C.A.; Blesken T.; Akdis M.; Alkan S.S.; Wuthrich B.; Heusser C.H.; Blaser K.
Dr. C.A. Akdis, Swiss Inst. of Allergy/Asthma Res., Obere Strasse 22, CH-7270 Davos Platz Switzerland
Journal of Allergy and Clinical Immunology (J. ALLERGY CLIN. IMMUNOL.) (United States) 1997, 99/3 (345-353)
CODEN: JACIB ISSN: 0091-6749
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 56

9/3/76 (Item 12 from file: 73)
DIALOG(R)File 73:EMBASE

06767813 EMBASE No: 1997049306
Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation - Characterization of membrane TNF-alpha
Higuchi M.; Nagasawa K.; Horiuchi T.; Oike M.; Ito Y.; Yasukawa M.; Niho Y.
M. Higuchi, I Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka 812-82 Japan
Clinical Immunology and Immunopathology (CLIN. IMMUNOL. IMMUNOPATHOL.) (United States) 1997, 82/2 (133-140)
CODEN: CLIIA ISSN: 0090-1229
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 35

9/3/77 (Item 13 from file: 73)
DIALOG(R)File 73:EMBASE

05669824 EMBASE No: 1994080407
Activated CD4sup + T cells induce CD40-dependent proliferation of human B cell precursors
Renard N.; Duvert V.; Blanchard D.; Banchereau J.; Saeland S.
Immunological Research Laboratory, Schering-Plough, 27 chemin des Poupliers,69571 Dardilly France
Journal of Immunology (J. IMMUNOL.) (United States) 1994, 152/4 (1693-1701)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

9/3/78 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12918630 21656620 PMID: 11797392
[Is it possible to treat diseases by manipulation of lymphocytes?]
Ogasawara K
Second Department of Pathology, Shiga University of Medical Science, School of Medicine, Ohtsu 520-2192.

Rinsho byori. The Japanese journal of clinical pathology (Japan) Dec 2001, 49 (12) p1225-32, ISSN 0047-1860 Journal Code: 2984781R
Document type: Journal Article; Review; Review, Tutorial ; English Abstract
Languages: JAPANESE
Main Citation Owner: NLM
Record type: Completed

9/3/79 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10452562 99451296 PMID: 10520003
Bryostatin and **CD40-ligand** enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
Kitada S; Zapata J M; Andreeff M; Reed J C
The Burnham Institute, Program on Apoptosis and Cell Death Research, La Jolla, California, USA.
British journal of haematology (ENGLAND) Sep 1999, 106 (4) p995-1004, ISSN 0007-1048 Journal Code: 0372544
Contract/Grant No.: CA-55164; CA; NCI; CA-69381; CA; NCI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/80 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10188320 99182270 PMID: 10084754
Central role for CD40/**CD40 ligand** (CD154) interactions in transplant rejection.
Denton M D; Reul R M; Dharnidharka V R; Fang J C; Ganz P; Briscoe D M
Department of Pediatrics, Children's Hospital, Boston, Massachusetts 02115, USA.
Pediatric transplantation (DENMARK) Feb 1998, 2 (1) p6-15, ISSN 1397-3142 Journal Code: 9802574
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/81 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09788182 98214894 PMID: 9554275
A novel method for enhancement of T independent responses.
Dullforce P; Sutton D; Heath A W
Division of Molecular and Genetic Medicine, University of Sheffield Medical School, U.K.
Developments in biological standardization (SWITZERLAND) 1998, 92 p195-8, ISSN 0301-5149 Journal Code: 0427140
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/82 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09737508 98180364 PMID: 9521069
Diminished expression of **CD40 ligand** may contribute to the defective humoral immunity in patients with MHC class II deficiency.
Nonoyama S; Etzioni A; Toru H; Ruggerie D P; Lewis D; Pollack S; Aruffo A ; Yata J I; Ochs H D
Department of Pediatrics, University of Washington, Seattle, USA. snonoyama.ped@med.tmd.ac.jp
European journal of immunology (GERMANY) Feb 1998, 28 (2) p589-98, ISSN 0014-2980 Journal Code: 1273201
Contract/Grant No.: HD17427; HD; NICHD
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/83 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09685356 98124483 PMID: 9464836
Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kappaB.
Yoshimoto T; Nagase H; Ishida T; Inoue J; Nariuchi H
Department of Allergology, The Institute of Medical Science, The University of Tokyo, Japan. yoshimot@ims.u-tokyo.ac.jp
European journal of immunology (GERMANY) Dec 1997, 27 (12) p3461-70, ISSN 0014-2980 Journal Code: 1273201
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/84 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09652283 98082887 PMID: 9422424
Blockade of the CD40-**CD40 ligand** pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
Lu L; Li W; Fu F; Chambers F G; Qian S; Fung J J; Thomson A W
Thomas E. Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh, Pennsylvania 15213, USA.
Transplantation (UNITED STATES) Dec 27 1997, 64 (12) p1808-15, ISSN 0041-1337 Journal Code: 0132144
Contract/Grant No.: R01 AI41011; AI; NIAID; R01 DK 49745; DK; NIDDK
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/85 (Item 8 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09369928 97244166 PMID: 9088975
CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells.
Bjorck P; Banchereau J; Flores-Romo L
Schering-Plough Laboratory for Immunological Research, Dardilly, France.
International immunology (ENGLAND) Mar 1997, 9 (3) p365-72, ISSN 0953-8178 Journal Code: 8916182
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM

Record type: Completed

9/3/86 (Item 9 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09306251 97206088 PMID: 9156649
Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.
Funakoshi S; Taub D D; Asai O; Hirano A; Ruscetti F W; Longo D L; Murphy W J
Jikei University School of Medicine, Tokyo, Japan.
Leukemia & lymphoma (SWITZERLAND) Jan 1997, 24 (3-4) p187-99, ISSN 1042-8194 Journal Code: 9007422
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/87 (Item 10 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08514909 95273359 PMID: 7538666
CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression.
Karmann K; Hughes C C; Schechner J; Fanslow W C; Pober J S
Molecular Cardiobiology Program, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, CT 06536, USA.
Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) May 9 1995, 92 (10) p4342-6, ISSN 0027-8424 Journal Code: 7505876
Contract/Grant No.: R37-HL-36003; HL; NHLBI; RO1-HL-51014; HL; NHLBI; T32-AR-07016; AR; NIAMS
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

9/3/88 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

136215413 CA: 136(14)215413z PATENT
Computer program and three-dimensional structure of complex of monoclonal antibody 5c8 and CD154 for designing and selecting CD154 agonists and antagonists for treating immunol. diseases
INVENTOR(AUTHOR): Karpusas, Michael; Hsu, Yen-ming; Taylor, Frederick R.; Zheng, Zhongli
LOCATION: USA
ASSIGNEE: Biogen, Inc.
PATENT: PCT International ; WO 200218445 A2 DATE: 20020307
APPLICATION: WO 2001US27352 (20010813) *US PV229933 (20000901) *US PV276452 (20010316)
PAGES: 470 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD;

TG

9/3/89 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

136215033 CA: 136(14)215033a JOURNAL
Co-stimulation blockade, hemophilic inhibitors and tolerance
AUTHOR(S): Qian, Jiahua; Saenko, Evgueni; Scott, David
LOCATION: Department of Immunology, Holland Laboratory of the American Red Cross, Rockville, MD, 20855, USA
JOURNAL: Thromb. Haemostasis DATE: 2001 VOLUME: 86 NUMBER: 6 PAGES: 1343-1344 CODEN: THHADQ ISSN: 0340-6245 LANGUAGE: English PUBLISHER: Schattauer GmbH

9/3/90 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

136036363 CA: 136(3)36363m PATENT
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
INVENTOR(AUTHOR): Anderson, Darrell R.; Pan, Li Zhen; Hanna, Nabil; Rastetter, William H.; Kloetzer, William S.
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200194586 A2 DATE: 20011213
APPLICATION: WO 2001US18098 (20010606) *US PV209584 (20000606)
PAGES: 130 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/13A; C07K-016/28B; A61K-039/395B; A61P-037/06B; A61K-048/00B; C12N-015/63B; C12N-015/86B; C12N-015/861B; C12N-015/867B; C12N-015/11B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/3/91 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135151637 CA: 135(11)151637v PATENT
CD40-binding APC-activating molecules
INVENTOR(AUTHOR): Thomas, David; De Boer, Mark; Res, Pieter C. J. M.; Simons, Peter J.
LOCATION: USA
ASSIGNEE: Tanox, Inc.
PATENT: PCT International ; WO 200156603 A1 DATE: 20010809
APPLICATION: WO 2001US3378 (20010201) *US PV178934 (20000201)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/00B; C07K-016/28B; C12N-005/10B; C12N-005/12B; C12N-015/00B; C12N-015/11B; C12N-015/13B; C12N-015/12B; C12N-015/63B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CN; CR; CU; CZ; DM; DZ; EE; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; RO; RU; SD; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM ; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI;

FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/3/92 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135136414 CA: 135(10)136414b PATENT
CD40 ligand adjuvant for respiratory syncytial virus
INVENTOR(AUTHOR): Tripp, Ralph A.; Anderson, Larry J.; Brown, Michael P.
LOCATION: USA
ASSIGNEE: Government of the United States of America, as Represented by the Secretary of the Department of Health and Human Services
PATENT: PCT International ; WO 200156602 A2 DATE: 20010809
APPLICATION: WO 2001US3584 (20010202) *US PV179905 (20000202)
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/39A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/3/93 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135018557 CA: 135(2)18557c PATENT
Treatment of autoimmune diseases by an agonistic CD40-binding protein
INVENTOR(AUTHOR): Mauri, Claudia; Mars, Leonaredus Theodorus; Londei, Marco
LOCATION: UK,
ASSIGNEE: The Mathilda and Terence Kennedy Institute of Rheumatology
PATENT: PCT International ; WO 0137870 A1 DATE: 20010531
APPLICATION: WO 2000GB4511 (20001127) *GB 9927757 (19991125)
PAGES: 41 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; G01N-033/53B; G01N-033/577B; A61P-037/02B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/3/94 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

134294513 CA: 134(21)294513s PATENT
Process for inducing functional tolerance to gene transfer products
INVENTOR(AUTHOR): Andersson, Goran K.
LOCATION: USA
ASSIGNEE: Biotransplant Incorporated
PATENT: PCT International ; WO 0125398 A2 DATE: 20010412
APPLICATION: WO 2000US26946 (20000929) *US PV157233 (19991001)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;

CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW ; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/3/95 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

134236228 CA: 134(17)236228s PATENT
CD40 ligand and CD40 agonist compositions and methods of use
INVENTOR(AUTHOR): Ahuja, Seema S.; Bonewald, Lynda F.
LOCATION: USA
ASSIGNEE: Board of Regents, the University of Texas System
PATENT: PCT International ; WO 200116180 A2 DATE: 20010308
APPLICATION: WO 2000US23276 (20000824) *US PV151250 (19990827)
PAGES: 117 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/705A; C07K-016/28B; A61K-038/17B; A61K-039/395B; A61P-019/10B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW ; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/3/96 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131270955 CA: 131(20)270955z PATENT
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
INVENTOR(AUTHOR): Armitage, Richard J.; Fanslow, William C.; Spriggs, Melanie K.
LOCATION: USA
ASSIGNEE: Immunex Corporation
PATENT: United States ; US 5961974 A DATE: 19991005
APPLICATION: US 249189 (19940524) *US 783707 (19911025) *US 805723 (19911205) *US 969703 (19921023)
PAGES: 59 pp., Cont.-in-part of U.S. Ser. No. 969,703, abandoned.
CODEN: USXXAM LANGUAGE: English CLASS: 424154100; C07K-016/28A; A61K-039/395B; C12N-005/12B

9/3/97 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131270947 CA: 131(20)270947y PATENT
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
INVENTOR(AUTHOR): Armitage, Richard J.; Fanslow, William C.; Spriggs, Melanie K.; Srinivasan, Subhashini; Gibson, Marylou G.; Morris, Arvia E.; McGrew, Jeffrey T.
LOCATION: USA
ASSIGNEE: Immunex Corporation
PATENT: United States ; US 5962406 A DATE: 19991005

APPLICATION: US 484624 (19950607) *US 783707 (19911025) *US 805723 (19911205) *US 969703 (19921023) *US 249189 (19940524)
PAGES: 64 pp., Cont.-in-part of U.S. Ser. No. 249,189. CODEN: USXXAM
LANGUAGE: English CLASS: 514008000; A61K-038/18A; C07K-014/435B

9/3/98 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129301687 CA: 129(23)301687d PATENT
Methods for proliferating and differentiating B cells with high density membrane CD40 ligand
INVENTOR(AUTHOR): Kehry, Marilyn; Castle, Brian
LOCATION: USA
ASSIGNEE: Boehringer Ingelheim Pharmaceuticals, Inc.
PATENT: United States ; US 5817516 A DATE: 19981006
APPLICATION: US 431055 (19950428) *US 234580 (19940428)
PAGES: 37 pp. Cont.-in-part of U.S. Ser. No. 234,580, abandoned. CODEN: USXXAM LANGUAGE: English CLASS: 435377000; C12N-005/02A; C12N-005/08B

9/3/99 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

128229364 CA: 128(19)229364f PATENT
Treatment of antigen presenting cells to modulate antigen presenting cell function
INVENTOR(AUTHOR): Brooks, Stephen P.; Tomasi, Thomas B.; Bernstein, Zale P.
LOCATION: USA
ASSIGNEE: Health Research Inc.
PATENT: PCT International ; WO 9810056 A1 DATE: 19980312
APPLICATION: WO 97US15431 (19970902) *US 25332 (19960903)
PAGES: 53 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-005/00A
DESIGNATED COUNTRIES: AU; CA; JP; KP; KR; NZ DESIGNATED REGIONAL: AT; BE ; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

9/3/100 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

128087637 CA: 128(8)87637w JOURNAL
Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5
AUTHOR(S): Ledbetter, Jeffrey A.; Francisco, Joseph A.; Siegall, Clay B.; Gilliland, Lisa K.; Hollenbaugh, Diane; Aruffo, Alejandro; Siadak, Anthony W.; Mischel-Petty, Nicole; Grosmaire, Laura S.; Gordon, Marcia L.; Brown, T. Joseph; Moran-Davis, Patti; Mittler, Robert S.; Kiener, Peter A.; Nadler, Steven G.
LOCATION: Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle , WA, 98121, USA
JOURNAL: Crit. Rev. Immunol. DATE: 1997 VOLUME: 17 NUMBER: 5 & 6
PAGES: 427-435 CODEN: CCRIDE ISSN: 1040-8401 LANGUAGE: English
PUBLISHER: Begell House, Inc.

9/3/101 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

127076013 CA: 127(6)76013t PATENT

Stimulation of antibody release by B lymphocytes with granulocyte-macrophage colony stimulating factor, interleukins, interferons, and universal T-cell epitopes
INVENTOR(AUTHOR): Mond, James J.; Snapper, Clifford M.
LOCATION: USA
ASSIGNEE: Henry M. Jackson Foundation for the Advancement of Military Medicine
PATENT: PCT International ; WO 9720940 A1 DATE: 19970612
APPLICATION: WO 96US19327 (19961205) *US 568343 (19951206)
PAGES: 60 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/62A; A61K-038/19B; A61K-038/20B; A61K-039/385B; A61K-039/44B
DESIGNATED COUNTRIES: AU; CA; JP DESIGNATED REGIONAL: AT; BE; CH; DE; DK ; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

9/3/102 (Item 15 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

125284972 CA: 125(22)284972r PATENT
Compositions and methods for stimulating antibody class switching
INVENTOR(AUTHOR): Mond, James J.; Snapper, Clifford M.
LOCATION: USA
ASSIGNEE: Uniformed Services University of the Health Sciences
PATENT: PCT International ; WO 9627390 A1 DATE: 960912
APPLICATION: WO 96US2263 (960307) *US 400322 (950308)
PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/385A; A61K-039/39B; A61K-038/20B; A61K-038/18B; A61K-038/17B; A61K-031/715B; A61K-039/385J; A61K-038/18J; A61K-038/17J; A61K-039/385K; A61K-038/17K; A61K-031/715K DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BB; BG; BR; BY; CA ; CH; CN; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK ; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML

9/3/103 (Item 16 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

124053716 CA: 124(5)53716y PATENT
High density membrane-bound CD40 ligand for proliferating and differentiating B cells
INVENTOR(AUTHOR): Kehry, Marilyn; Castle, Brian E.
LOCATION: USA
ASSIGNEE: Boehringer Ingelheim Pharmaceuticals, Inc.
PATENT: PCT International ; WO 9529935 A1 DATE: 951109
APPLICATION: WO 95US5448 (950428) *US 234580 (940428)
PAGES: 73 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/00A; C07K-014/705B; C07K-014/71B; C07K-014/725B; C12N-005/00B; C12N-005/02B; C12N-005/06B DESIGNATED COUNTRIES: CA; JP; MX DESIGNATED REGIONAL: AT; BE ; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

9/3/104 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

123141712 CA: 123(11)141712d PATENT
Compositions and method for stimulating antibody release by B lymphocytes
INVENTOR(AUTHOR): Snapper, Clifford M.; Mond, James J.
LOCATION: USA
ASSIGNEE: United States Dept. of the Army

ds

Set	Items	Description
S1	12	FGK45
S2	7	RD S1 (unique items)
S3	112	AGONIST? (10N)(ANTI(W)CD40)
S4	55	RD S3 (unique items)

? t s4/3/all

4/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13741782 BIOSIS NO.: 200200370603
Activation of antigen presenting cells (APCs) through toll like receptor (TLR) 9 or CD40 reverses tolerance and precipitates autoimmune disease.
AUTHOR: Segal Benjamin Matthew(a); Ichikawa Hiroshi Travis
AUTHOR ADDRESS: (a)Neurology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 605, Rochester, NY, 14642**USA
JOURNAL: FASEB Journal 16 (5):pA1066 March 22, 2002
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of Professional Research Scientists on Experimental Biology New Orleans, Louisiana, USA April 20-24, 2002
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13735185 BIOSIS NO.: 200200364006
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.
AUTHOR: Nguyen Linh T; Elford Alisha R; Murakami Kiichi; Garza Kristine M; Schoenberger Stephen P; Odermatt Bernhard; Speiser Daniel E; Ohashi Pamela S(a)
AUTHOR ADDRESS: (a)Ontario Cancer Institute, 610 University Ave., 8-327, Toronto, ON, M5G 2M9**Canada E-Mail: pohashi@uhnres.utoronto.ca
JOURNAL: Journal of Experimental Medicine 195 (4):p423-435 February 18, 2002
MEDIUM: print
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13730225 BIOSIS NO.: 200200359046
Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8+ T cells produce active immune unresponsiveness.
AUTHOR: Ferguson Thomas A(a); Herndon John; Elzey Bennett; Griffith Thomas S; Schoenberger Steve; Green Douglas R
AUTHOR ADDRESS: (a)Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, 660 South Euclid Street, Box 8096, St. Louis, MO, 63110**USA E-Mail: Ferguson@vision.wust1.edu
JOURNAL: Journal of Immunology 168 (11):p5589-5595 June 1, 2002
MEDIUM: print
ISSN: 0022-1767

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13723317 BIOSIS NO.: 200200352138
CD154-dependent priming of diabetogenic CD4+ T cells dissociated from activation of antigen-presenting cells.
AUTHOR: Amrani Abdelaziz; Serra Pau; Yamanouchi Jun; Han Bingye; Thiessen Shari; Verdaguer Joan; Santamaria Pere(a)
AUTHOR ADDRESS: (a)Department of Microbiology and Infectious Diseases and Julia McFarlane Diabetes Research Center, Faculty of Medicine, University of Calgary, 3330 Hospital Drive N.W., Calgary, AB, T2N 4N1**Canada E-Mail: psantama@ucalgary.ca
JOURNAL: Immunity 16 (5):p719-732 May, 2002
MEDIUM: print
ISSN: 1074-7613
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13722623 BIOSIS NO.: 200200351444
CD40 ligation in the presence of self-reactive CD8 T cells leads to severe immunopathology.
AUTHOR: Roth Evelyn; Schwartzkopff Johannes; Pircher Hanspeter(a)
AUTHOR ADDRESS: (a)Department of Immunology, Institute for Medical Microbiology and Hygiene, University of Freiburg, Hermann-Herder-Strasse 11, D-79104, Freiburg**Germany E-Mail: pircher@UKL.uni-freiburg.de
JOURNAL: Journal of Immunology 168 (10):p5124-5129 May 15, 2002
MEDIUM: print
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13680681 BIOSIS NO.: 200200309502
CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
AUTHOR: van Mierlo Geertje J D; den Boer Annemieke Th; Medema Jan Paul; van der Voort Ellen I H; Fransen Marieke F; Offringa Rienk; Melief Cornelis J M; Toes Rene E M(a)
AUTHOR ADDRESS: (a)Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, 2300 RC, Leiden**Netherlands E-Mail: R.E.M.Toes@Lumc.nl
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 99 (8):p5561-5566 April 16, 2002
MEDIUM: print
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13631642 BIOSIS NO.: 200200260463
Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response.
AUTHOR: Osada Takuya(a); Nagawa Hirokazu; Takahashi Tsuyoshi; Tsuno Nelson H; Kitayama Joji; Shibata Yoichi
AUTHOR ADDRESS: (a)Department of Surgery, Duke University Medical Center, Research Dr, 407 MSRB, Durham, NC, 27710**USA E-Mail: osada001@mc.duke.edu
JOURNAL: Journal of Immunotherapy 25 (2):p176-184 March-April, 2002
MEDIUM: print
ISSN: 1524-9557
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13612394 BIOSIS NO.: 200200241215
Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma.
AUTHOR: Weng Wen-Kai(a); Wang Changyu; Chu Keting; Levy Ronald(a)
AUTHOR ADDRESS: (a)Medicine/Oncology, Stanford University, Stanford, CA** USA
JOURNAL: Blood 98 (11 Part 1):p466a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

4/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13581112 BIOSIS NO.: 200200209933
Retinoic acid and CD40 ligand co-operate to promote induction of immune accessory molecules and immune responses to human myeloid leukemia cells.
AUTHOR: Kato Kazunori(a); Yoshida Mitsuzi(a); Takaue Yoichi(a); Kipps Thomas J; Wakasugi Hiro(a)
AUTHOR ADDRESS: (a)Pharmacology Div., Natl. Cancer Ctr. Res. Inst., Chuoku, Tokyo**Japan
JOURNAL: Blood 98 (11 Part 1):p589a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

4/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13448324 BIOSIS NO.: 200200077145
Enhancing effects of anti-CD40 treatment on the immune response of SCID-bovine mice to Trypanosoma congolense infection.
AUTHOR: Haas Karen M; Taylor Katherine A; MacHugh Niall D; Kreeger John M; Estes D Mark(a)
AUTHOR ADDRESS: (a)Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, 65211**USA E-Mail: EstesD@missouri.edu
JOURNAL: Journal of Leukocyte Biology 70 (6):p931-940 December, 2001
MEDIUM: print
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13285840 BIOSIS NO.: 200100492989
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.
AUTHOR: Hawiger Daniel; Inaba Kayo; Dorsett Yair; Guo Ming; Mahnke Karsten; Rivera Miguel; Ravetch Jeffrey V; Steinman Ralph M; Nussenzweig Michel C (a)
AUTHOR ADDRESS: (a)Department of Molecular Immunology, HHMI, 1230 York Ave., RRB Rm. 470, New York, NY, 10021: nussen@mail.rockefeller.edu**USA
JOURNAL: Journal of Experimental Medicine 194 (6):p769-779 September 17, 2001
MEDIUM: print
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13267172 BIOSIS NO.: 200100474321
CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination.
AUTHOR: Kedl Ross M(a); Jordan Michael; Potter Terence; Kappler John; Marrack Philippa; Dow Steven
AUTHOR ADDRESS: (a)3M Center, 3M Pharmaceuticals, Building 270-2S-06, St. Paul, MN, 55144-1000: rmkedl@mmm.com**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 98 (19):p10811-10816 September 11, 2001
MEDIUM: print
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13004788 BIOSIS NO.: 200100211937
Stimulation of dendritic cells via CD40 enhances immune responses to Mycobacterium tuberculosis infection.
AUTHOR: Demangel Caroline; Palendira Umaimainthan; Feng Carl G; Heath Andrew W; Bean Andrew G D; Britton Warwick J(a)
AUTHOR ADDRESS: (a)Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW, 2042: wbritton@medicine.usyd.edu.au**Australia
JOURNAL: Infection and Immunity 69 (4):p2456-2461 April, 2001
MEDIUM: print
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12980704 BIOSIS NO.: 200100187853
Increase in tonsillar germinal centre B-1 cell numbers in IgA nephropathy (IgAN) patients and reduced susceptibility to Fas-mediated apoptosis.
AUTHOR: Kodama S; Suzuki M; Arita M; Mogi G(a)
AUTHOR ADDRESS: (a)Department of Otolaryngology, Oita Medical University, Hazama-machi, Oita, 879-5593: gmog@oita-med.ac.jp**Japan
JOURNAL: Clinical and Experimental Immunology 123 (2):p301-308 February, 2001
MEDIUM: print
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12954277 BIOSIS NO.: 200100161426
CD40 ligation for immunotherapy of solid tumours.
AUTHOR: Todryk Stephen M; Tutt Alison L; Green Michael H A; Smallwood J A; Halanek Nicole; Dalgleish Angus G; Glennie Martin J(a)
AUTHOR ADDRESS: (a)Tenovus Research Laboratory, Cancer Sciences Division, School of Medicine, General Hospital, Southampton, SO16 6YD: M.J.Glennie@soton.ac.uk**UK
JOURNAL: Journal of Immunological Methods 248 (1-2):p139-147 1 February, 2001
MEDIUM: print
ISSN: 0022-1759
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12884199 BIOSIS NO.: 200100091348
Anti-CD40 treatment of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-exposed C57Bl/6 mice induces activation of antigen presenting cells yet fails to

overcome TCDD-induced suppression of allograft immunity.
AUTHOR: Shepherd David M(a); Steppan Linda B; Hedstrom Olaf R; Kerkvliet Nancy I
AUTHOR ADDRESS: (a)Department of Environmental and Molecular Toxicology, Oregon State University, Agricultural Life Sciences Building, Room 1007, Corvallis, OR, 97331: David.Shepherd@orst.edu**USA
JOURNAL: Toxicology and Applied Pharmacology 170 (1):p10-22 January 1, 2001
MEDIUM: print
ISSN: 0041-008X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12832356 BIOSIS NO.: 200100039505
Therapeutic activity of **agonistic anti-CD40** mAb in a chronic autoimmune inflammatory process.
AUTHOR: Mauri C(a); Mars L T(a); Londei M(a)
AUTHOR ADDRESS: (a)Kennedy Institute of Rheumatology, London**UK
JOURNAL: FASEB Journal 14 (6):pA1101 April 20, 2000
MEDIUM: print
CONFERENCE/MEETING: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society Seattle, Washington, USA May 12-16, 2000
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12821470 BIOSIS NO.: 200100028619
B cell immunopoiesis: Visualizing the impact of CD40 engagement on the course of T cell-independent immune responses in an Ig transgenic system.
AUTHOR: Erickson Loren D; Vogel Laura A; Cascalho Marilia; Wong Jamie; Wabl Matthias; Durell Brigit G; Noelle Randolph J(a)
AUTHOR ADDRESS: (a)Department of Microbiology, Dartmouth Medical School, 1 Medical Center Drive, Lebanon, NH, 03756: rjn@dartmouth.edu**USA
JOURNAL: European Journal of Immunology 30 (11):p3121-3131 November, 2000
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/19 (Item 19 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12666263 BIOSIS NO.: 200000419765
Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process.
AUTHOR: Mauri Claudia; Mars Lennart T; Londei Marco(a)

AUTHOR ADDRESS: (a)The Kennedy Institute of Rheumatology, Imperial College School of Medicine, 1 Aspenlea Road, London, W6 8LH**UK
JOURNAL: Nature Medicine 6 (6):p673-679 June, 2000
MEDIUM: print
ISSN: 1078-8956
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12604864 BIOSIS NO.: 200000358366
Agonistic properties and in vivo antitumor activity of the **anti -CD40** antibody SGN-14.
AUTHOR: Francisco Joseph A; Donaldson Karen L; Chace Dana; Siegall Clay B; Wahl Alan F(a)
AUTHOR ADDRESS: (a)Department of Biochemistry, Seattle Genetics, Inc., 22215 26th Avenue SE, Bothell, WA, 98021**USA
JOURNAL: Cancer Research 60 (12):p3225-3231 June 15, 2000
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/21 (Item 21 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12571721 BIOSIS NO.: 200000325223
CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes.
AUTHOR: Moodycliffe Angus M; Shreedhar Vijay; Ullrich Stephen E; Walterscheid Jeffrey; Bucana Corazon; Kripke Margaret L; Flores-Romo Leopoldo(a)
AUTHOR ADDRESS: (a)Inq.: Ms. Sue Adams, Dept. of Immunology-178, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030**USA
JOURNAL: Journal of Experimental Medicine 191 (11):p2011-2020 June 5, 2000
MEDIUM: print
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12538090 BIOSIS NO.: 200000291592
Dexamethasone and cyclosporin A affect the maturation of monocyte-derived dendritic cells differently.
AUTHOR: Manome Hideaki; Aiba Setsuy; Singh Sanjay; Yoshino Yumiko; Tagami Hachiro
AUTHOR ADDRESS: (a)Department of Dermatology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aobaku, Sendai, 980-8574**Japan
JOURNAL: International Archives of Allergy and Immunology 122 (1):p76-84

May, 2000
MEDIUM: print.
ISSN: 1018-2438
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12464970 BIOSIS NO.: 200000218472
Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis.
AUTHOR: Samten Buka; Thomas Elaine K; Gong Jianhua; Barnes Peter F(a)
AUTHOR ADDRESS: (a)Center for Pulmonary and Infectious Disease Control, University of Texas Health Center at Tyler, 11937 U.S. Highway 271, Tyler, TX, 75708-3154**USA
JOURNAL: Infection and Immunity 68 (5):p3002-3006 May, 2000
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/24 (Item 24 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12401824 BIOSIS NO.: 200000155326
Therapeutic activity of **anti CD40 agonistic** mAbs in an autoimmune inflammatory process.
AUTHOR: Mars Lennart T(a); Mauri Claudia(a); Londei Marco(a)
AUTHOR ADDRESS: (a)Kennedy Institute of Rheumatology, Hammersmith, 1 Aspenlea Road, W6 8LH, London**UK
JOURNAL: Immunology. 98 (suppl. 1):p100 Dec., 1999
CONFERENCE/MEETING: Joint Congress of the British Society for Immunology and the British Society for Allergy & Clinical Immunology. Harrogate, England, UK November 30-December 03, 1999
SPONSOR: British Society for Allergy & Clinical Immunology
ISSN: 0019-2805
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/25 (Item 25 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12355175 BIOSIS NO.: 200000108677
Pararosaniline fixation for detection of co-stimulatory molecules, cytokines, and specific antibody.
AUTHOR: Schrijver Ingrid A(a); Melief Marie-Jose; van Meurs Marjan; Companjen Arjen R; Laman Jon D
AUTHOR ADDRESS: (a)Dept. of Immunology, Erasmus University Rotterdam, 3000 DR, Rotterdam**Netherlands
JOURNAL: Journal of Histochemistry and Cytochemistry 48 (1):p95-103 Jan., 2000
ISSN: 0022-1554
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/26 (Item 26 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12349382 BIOSIS NO.: 200000102884
CD40 signals apoptosis through FAN-regulated activation of the sphingomyelin-ceramide pathway.
AUTHOR: Segui Bruno; Andrieu-Abadie Nathalie; Adam-Klages Sabine; Meilhac Olivier; Kreder Dirk; Garcia Virginie; Bruno Alain P; Jaffrezou Jean-Pierre; Salvayre Robert; Kroenke Martin; Levade Thierry(a)
AUTHOR ADDRESS: (a)Laboratoire de Biochimie, INSERM U466, Institut Louis Bugnard, Centre Hospitalier Universitaire Rangueil, 1 Avenue Jean Poulhes, Batiment L3, F-31403, Toulouse Cedex 4**France
JOURNAL: Journal of Biological Chemistry 274 (52):p37251-37258 Dec. 24, 1999
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/27 (Item 27 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11403258 BIOSIS NO.: 199800184590
The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb.
AUTHOR: Ferlin Walter G; Von Der Weid Thierry; Cottrez Francoise; Ferrick David A; Coffman Robert L; Howard Maureen C(a)
AUTHOR ADDRESS: (a)Anergen Inc., 301 Penobscot Dr., Redwood City, CA 94036 **USA
JOURNAL: European Journal of Immunology 28 (2):p525-531 Feb., 1998
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/28 (Item 28 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11117709 BIOSIS NO.: 199799738854
Precursor B cells for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination.
AUTHOR: Hirose Sachiko; Yan Kwangseok; Abe Masaaki; Jiang Yi; Hamano Yoshitomo; Tsurui Hiromicfhi; Shirai Toshikazu(a)
AUTHOR ADDRESS: (a)Dep. Pathol., Juntendo Univ. Sch. Med, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113**Japan
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 94 (17):p9291-9295 1997
ISSN: 0027-8424
RECORD TYPE: Abstract
LANGUAGE: English

4/3/29 (Item 29 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

09436213 BIOSIS NO.: 199497444583
Monoclonal antibodies to murine CD40 define two distinct functional epitopes.
AUTHOR: Heath Andrew W; Wu Wei Wei; Howard Maureen C(a)
AUTHOR ADDRESS: (a)DNAX Res. Inst., 901 California Ave., Palo Alto, CA 94304**USA
JOURNAL: European Journal of Immunology 24 (8):p1828-1834 1994
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/30 (Item 30 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

07861309 BIOSIS NO.: 000092120675
STIMULATION OF PROTEIN TYROSINE PHOSPHORYLATION PHOSPHOINOSITIDE TURNOVER AND MULTIPLE PREVIOUSLY UNIDENTIFIED SERINE THREONINE-SPECIFIC PROTEIN KINASES BY THE PAN-B-CELL RECEPTOR CD40-BP50 AT DISCRETE DEVELOPMENTAL STAGES OF HUMAN B-CELL ONTOGENY
AUTHOR: UCKUN F M; SCHIEVEN G L; DIBIRDIK I; CHANDAN-LANGLIE M; TUEL-AHLGREN L; LEDBETTER J A
AUTHOR ADDRESS: TUMOR IMMUNOLOGY LABORATORY, BOX 356, UMHC, 420 DELAWARE ST. S.E., MINNEAPOLIS, MINN. 55455.
JOURNAL: J BIOL CHEM 266 (26). 1991. 17478-17485. 1991
FULL JOURNAL NAME: Journal of Biological Chemistry
CODEN: JBCHA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

4/3/31 (Item 31 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

07422961 BIOSIS NO.: 000091028950
ANALYSIS OF EXPRESSION AND FUNCTION OF CD40 ON NORMAL AND LEUKEMIC HUMAN B CELL PRECURSORS
AUTHOR: LAW C-L; WORMANN B; LEBIEN T W
AUTHOR ADDRESS: BOX 609, UMHC, DEP. LAB. MED. PATHOL., UNIV. MINN., MINNEAPOLIS, MINN. 55455, USA.
JOURNAL: LEUKEMIA (BALTIMORE) 4 (11). 1990. 732-738. 1990
FULL JOURNAL NAME: LEUKEMIA (Baltimore)
CODEN: LEUKE
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

4/3/32 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11639282 EMBASE No: 2002211352
CD154-dependent priming of diabetogenic CD4SUP+ T cells dissociated from activation of antigen-presenting cells
Amrani A.; Serra P.; Yamanouchi J.; Han B.; Thiessen S.; Verdaguer J.; Santamaria P.
P. Santamaria, Julia McFarlane Diabetes Res. Center, University of Calgary, Faculty of Medicine, 3330 Hospital Drive NW, Calgary, Alta. T2N

4N1 Canada
AUTHOR EMAIL: psantama@ucalgary.ca
Immunity (IMMUNITY) (United States) 2002, 16/5 (719-732)
CODEN: IUNIE ISSN: 1074-7613
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 67

4/3/33 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

11617823 EMBASE No: 2002189482
Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8SUP+ T cells produce active immune unresponsiveness
Ferguson T.A.; Herndon J.; Elzey B.; Griffith T.S.; Schoenberger S.; Green D.R.
Dr. T.A. Ferguson, Department of Ophthalmology, Washington Univ. School of Medicine, Box 8096, 660 South Euclid Street, St. Louis, MO 63110 United States
AUTHOR EMAIL: Ferguson@vision.wustl.edu
Journal of Immunology (J. IMMUNOL.) (United States) 01 JUN 2002, 168/11 (5589-5595)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 38

4/3/34 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

11575762 EMBASE No: 2002147301
CD40 stimulation leads to effective therapy of CD40SUP- tumors through induction of strong systemic cytotoxic T lymphocyte immunity
Van Mierlo G.J.D.; Den Boer A.T.; Medema J.P.; Van der Voort E.I.H.; Fransen M.F.; Offringa R.; Melief C.J.M.; Toes R.E.M.
R.E.M. Toes, Departments of Immunohematology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden Netherlands
AUTHOR EMAIL: R.E.M.Toes@Lumc.nl
Proceedings of the National Academy of Sciences of the United States of America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 16 APR 2002, 99/8 (5561-5566)
CODEN: PNASA ISSN: 0027-8424
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 39

4/3/35 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

11404457 EMBASE No: 2001412078
Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8SUP+ T cells in vitro, whereas CD40 ligation is essential
Kelleher M.; Beverley P.C.L.
Dr. M. Kelleher, Edward Jenner Inst. for Vacc. Res., Compton, Berkshire RG20 7NN United Kingdom
AUTHOR EMAIL: michelle.kelleher@jenner.ac.uk
Journal of Immunology (J. IMMUNOL.) (United States) 01 DEC 2001,

167/11 (6247-6255)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 52

4/3/36 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE

11317747 EMBASE No: 2001329877
CD40 stimulation accelerates deletion of tumor-specific CD8SUP+ T cells in the absence of tumor-antigen vaccination
Kedl R.M.; Jordan M.; Potter T.; Kappler J.; Marrack P.; Dow S.
R.M. Kedl, 3M Pharmaceuticals, 3M Center, St. Paul, MN 55144-1000 United States
AUTHOR EMAIL: rmkedl@mmm.com
Proceedings of the National Academy of Sciences of the United States of America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 11 SEP 2001, 98/19 (10811-10816)
CODEN: PNASA ISSN: 0027-8424
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 50

4/3/37 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE

11285558 EMBASE No: 2001295264
Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance
Den Boer A.Th.; Diehl L.; Van Mierlo G.J.D.; Van der Voort E.I.H.; Fransen M.F.; Krimpenfort P.; Melief C.J.M.; Offringa R.; Toes R.E.M.
Dr. A.Th. Den Boer, Department of Immunohematology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden Netherlands
AUTHOR EMAIL: boer a@mail.medfac.leidenuniv.nl
Journal of Immunology (J. IMMUNOL.) (United States) 01 SEP 2001, 167/5 (2522-2528)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 35

4/3/38 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE

11214910 EMBASE No: 2001221724
IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells
Nakae S.; Asano M.; Horai R.; Sakaguchi N.; Iwakura Y.
Dr. Y. Iwakura, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639 Japan
AUTHOR EMAIL: iwakura@ims.utokyo.ac.jp
Journal of Immunology (J. IMMUNOL.) (United States) 01 JUL 2001, 167/1 (90-97)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 43

4/3/39 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE

11121041 EMBASE No: 2001134778
CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
Rolph M.S.; Kaufmann S.H.E.
Dr. M.S. Rolph, Heart Research Institute, 145 Missenden Road, Camperdown, Sydney 2050 Australia
AUTHOR EMAIL: m.rolph@hri.org.au
Journal of Immunology (J. IMMUNOL.) (United States) 15 APR 2001, 166/8 (5115-5121)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 40

4/3/40 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE

11117336 EMBASE No: 2001140203
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation
Hixon J.A.; Blazar B.R.; Anver M.R.; Wiltrout R.H.; Murphy W.F.
W.J. Murphy, SAIC-Frederick, NCI-FCRDC, Bldg. 567, Frederick, MD 21702 United States
AUTHOR EMAIL: murphyw@mail.ncifcrf.gov
Biology of Blood and Marrow Transplantation (BIOL. BLOOD MARROW TRANSPLANT.) (United States) 2001, 7/3 (136-143)
CODEN: BBMTF ISSN: 1083-8791
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 20

4/3/41 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE

11000509 EMBASE No: 2001033948
Anti-CD40 treatment of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-exposed C57BI/6 mice induces activation of antigen presenting cells yet fails to overcome TCDD-induced suppression of allograft immunity
Shepherd D.M.; Steppan L.B.; Hedstrom O.R.; Kerkvliet N.I.
D.M. Shepherd, Dept. of Environ./Molecular Toxicol., Agricultural Life Sciences Building, Oregon State University, Corvallis, OR 97331 United States
AUTHOR EMAIL: David.Shepherd@orst.edu
Toxicology and Applied Pharmacology (TOXICOL. APPL. PHARMACOL.) (United States) 01 JAN 2001, 170/1 (10-22)
CODEN: TXAPA ISSN: 0041-008X
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 43

4/3/42 (Item 11 from file: 73)
DIALOG(R)File 73:EMBASE

10986051 EMBASE No: 2001029655
Role of CD40 in a T cell-mediated negative regulation of Ig production
Majlessi L.; Bordenave G.
Dr. G. Bordenave, Unite d'Immunophysiologie Molec., Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15 France
AUTHOR EMAIL: gbordena@pasteur.fr
Journal of Immunology (J. IMMUNOL.) (United States) 15 JAN 2001, 166/2 (841-847)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 42

4/3/43 (Item 12 from file: 73)
DIALOG(R)File 73:EMBASE

10532821 EMBASE No: 1999417584
Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells
Baccam M.; Bishop G.A.
G.A. Bishop, Department of Microbiology, University of Iowa, Iowa City, IA 52242 United States
AUTHOR EMAIL: gail-bishop@uiowa.edu
European Journal of Immunology (EUR. J. IMMUNOL.) (Germany) 1999, 29/12 (3855-3866)
CODEN: EJIMA ISSN: 0014-2980
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 44

4/3/44 (Item 13 from file: 73)
DIALOG(R)File 73:EMBASE

07928705 EMBASE No: 1999402576
Generation of mature dendritic cells from a CD14sup + cell line (XS52) by IL-4, TNF-alpha, IL-1beta, and **agonistic anti-CD40** monoclonal antibody
Yamada N.; Katz S.I.
Dr. S.I. Katz, Dermatology Branch, National Cancer Institute, Building 10, Bethesda, MD 20892 United States
AUTHOR EMAIL: skatz@box-s.nih.gov
Journal of Immunology (J. IMMUNOL.) (United States) 15 NOV 1999, 163/10 (5331-5337)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33

4/3/45 (Item 14 from file: 73)
DIALOG(R)File 73:EMBASE

07807833 EMBASE No: 1999297301
Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation
Shepherd D.M.; Kerkvliet N.I.
Dr. N.I. Kerkvliet, Dept. of Envtl./Molecular Toxicology, ALS 1007,

Oregon State University, Corvallis, OR 97331 United States
AUTHOR EMAIL: Nancy.Kerkvliet@orst.edu
Journal of Immunology (J. IMMUNOL.) (United States) 01 SEP 1999, 163/5 (2470-2477)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 64

4/3/46 (Item 15 from file: 73)
DIALOG(R)File 73:EMBASE

07735425 EMBASE No: 1999217763
CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion.
Maxwell J.R.; Campbell J.D.; Kim C.H.; Vella A.T.
Dr. A.T. Vella, 220 Nash Hall, Department of Microbiology, Oregon State University, Corvallis, OR 97331 United States
AUTHOR EMAIL: vellaa@bcc.orst.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 FEB 1999, 162/4 (2024-2034)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 87

4/3/47 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13495894 22181549 PMID: 12193753
Activation of APCs Through CD40 or Toll-Like Receptor 9 Overcomes Tolerance and Precipitates Autoimmune Disease.
Ichikawa Hiroshi T; Williams Lucas P; Segal Benjamin M
Departments of. Neurology and Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642.
Journal of immunology (Baltimore, Md. : 1950) (United States) Sep 1 2002, 169 (5) p2781-7, ISSN 0022-1767 Journal Code: 2985117R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Process

4/3/48 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12918630 21656620 PMID: 11797392
[Is it possible to treat diseases by manipulation of lymphocytes?]
Ogasawara K
Second Department of Pathology, Shiga University of Medical Science, School of Medicine, Ohtsu 520-2192.
Rinsho byori. The Japanese journal of clinical pathology (Japan) Dec 2001, 49 (12) p1225-32, ISSN 0047-1860 Journal Code: 2984781R
Document type: Journal Article; Review; Review, Tutorial ; English Abstract
Languages: JAPANESE
Main Citation Owner: NLM
Record type: Completed

4/3/49 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

12785213 21672719 PMID: 11814234
Mechanisms of mouse T lymphocyte-induced suppression of the IgG2ab allotype and T lymphocyte tolerance to IgG2ab.
Majlessi L; Bordenave G
Unite d'Immunophysiologie Moleculaire, Institut Pasteur, Paris, France. lmajless@pasteur.fr
Archivum immunologiae et therapiae experimentalis (Poland) 2001, 49 (6) p407-15, ISSN 0004-069X Journal Code: 0114365
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Process

4/3/50 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12682552 21571686 PMID: 11714787
Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
Kelleher M; Beverley P C
The Edward Jenner Institute for Vaccine Research, Compton, Berkshire, United Kingdom. michelle.kelleher@jenner.ac.uk
Journal of immunology (Baltimore, Md. : 1950) (United States) Dec 1 2001, 167 (11) p6247-55, ISSN 0022-1767 Journal Code: 2985117R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

4/3/51 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10488448 20021827 PMID: 10553056
Generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-alpha, IL-1 beta, and **agonistic anti-CD40** monoclonal antibody.
Yamada N; Katz S I
Dermatology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Journal of immunology (Baltimore, Md. : 1950) (UNITED STATES) Nov 15 1999, 163 (10) p5331-7, ISSN 0022-1767 Journal Code: 2985117R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

4/3/52 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09788182 98214894 PMID: 9554275
A novel method for enhancement of T independent responses.
Dullforce P; Sutton D; Heath A W
Division of Molecular and Genetic Medicine, University of Sheffield Medical School, U.K.
Developments in biological standardization (SWITZERLAND) 1998, 92 p195-8, ISSN 0301-5149 Journal Code: 0427140
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM

Record type: Completed

4/3/53 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

135151637 CA: 135(11)151637v PATENT
CD40-binding APC-activating molecules
INVENTOR(AUTHOR): Thomas, David; De Boer, Mark; Res, Pieter C. J. M.; Simons, Peter J.
LOCATION: USA
ASSIGNEE: Tanox, Inc.
PATENT: PCT International ; WO 200156603 A1 DATE: 20010809
APPLICATION: WO 2001US3378 (20010201) *US PV178934 (20000201)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/00B; C07K-016/28B; C12N-005/10B; C12N-005/12B; C12N-015/00B; C12N-015/11B; C12N-015/13B; C12N-015/12B; C12N-015/63B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CN; CR; CU; CZ; DM; DZ; EE; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; RO; RU; SD; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

4/3/54 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

134236228 CA: 134(17)236228s PATENT
CD40 ligand and CD40 agonist compositions and methods of use
INVENTOR(AUTHOR): Ahuja, Seema S.; Bonewald, Lynda F.
LOCATION: USA
ASSIGNEE: Board of Regents, the University of Texas System
PATENT: PCT International ; WO 200116180 A2 DATE: 20010308
APPLICATION: WO 2000US23276 (20000824) *US PV151250 (19990827)
PAGES: 117 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/705A; C07K-016/28B; A61K-038/17B; A61K-039/395B; A61P-019/10B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

4/3/55 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

131252537 CA: 131(19)252537k PATENT
Human interleukin-4 antagonist/agonist screens
INVENTOR(AUTHOR): De Vries, Jan E.; Jenh, Chung-her; Narula, Satwant K.; Zavodny, Paul J.
LOCATION: USA
ASSIGNEE: Schering Corporation
PATENT: United States ; US 5958707 A DATE: 19990928
APPLICATION: US 453024 (19950530) *US 770081 (19911003) *US 869914 (19920416) *US 70162 (19930528)

PAGES: 23 pp., Division of U.S. Ser. No. 70,162. CODEN: USXXAM
LANGUAGE: English CLASS: 435007200; G01N-033/53A
?

```
s (cd40)(10n)(antibod?)(dendritic)
           15400  CD40
               0  ANTIBOD?)(DENDRITIC)
      S3       0  (CD40)(10N)(ANTIBOD?)(DENDRITIC)
? s (cd40)(10n)(antibod?)(10n)(dendritic)
           15400  CD40
         1445964  ANTIBOD?
           80316  DENDRITIC
      S4      88  (CD40)(10N)(ANTIBOD?)(10N)(DENDRITIC)
? rd s4
...examined 50 records  (50)
...completed examining records
      S5      66  RD S4 (unique items)
? s s5 and py<2000
Processing
Processing
              66  S5
        39951254  PY<2000
      S6      25  S5 AND PY<2000
? t s6/7/all

 6/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12340942   BIOSIS NO.: 200000094444
An agonist anti-human CD40 monoclonal antibody that induces
  dendritic cell formation and maturation and inhibits proliferation
  of a myeloma cell line.
AUTHOR: Zhou Zhao-Hua; Wang Jiang-Fang; Wang Yue-Dan; Qiu Yue-Hua; Pan
  Jian-Zhong; Xie Wei; Jiang Lin-Yu; Klein Bernard; Zhang Xue-Guang(a)
AUTHOR ADDRESS: (a)Department of Immunology, Suzhou Medical College,
  Suzhou, 215007**China
JOURNAL: Hybridoma  18 (6):p471-478 Dec., 1999
ISSN: 0272-457X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: CD40, a 48-50 KD cell membrane molecule, member of the nerve
  growth factor receptor and tumor necrosis factor receptor superfamily, is
  an important costimulatory molecule during the immune response. Anti-CD40
  monoclonal antibody (MAb) has been shown earlier to costimulate with IgM
  or phorbol esters resting B cells to proliferate, differentiate, secrete
  immunoglobulins, and switch isotype. Here we report on an agonistic mouse
  anti-human CD40 MAb 5C11. The specificity of this MAb was verified by
  flow cytometry, Western blotting, and competition with anti-CD40 MAb 89.
  We studied the effects of MAb 5C11 on a multimyeloma cell line, XG2, that
  expresses the CD40 antigen strongly and found that this MAb caused the
  homotypic aggregation of XG2, strongly suppressed XG2 proliferation, and
  led to its apoptosis after 24 hr of treatment. Interestingly, MAb 5C11
  also triggered the generation, proliferation, and maturation of dendritic
  cells from peripheral blood monocytes, either by itself or in combination
  with GM-CSF and IL-4.


 6/7/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12122250   BIOSIS NO.: 199900417099
Interleukin-18 synthesis and secretion by dendritic cells are modulated by
  interaction with antigen-specific T cells.
```

AUTHOR: Gardella Stefania; Andrei Cristina; Costigliolo Sara; Poggi Alessandro; Zocchi M Raffaella; Rubartelli Anna(a)
AUTHOR ADDRESS: (a)National Institute for Cancer Research, Largo Rosanna Benzi, 10, 16132, Genova**Italy
JOURNAL: Journal of Leukocyte Biology 66 (2):p237-241 Aug., **1999**
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: We show that interleukin-18 is constitutively produced by dendritic cells; synthesis and secretion are poorly affected by maturative stimuli. Challenge of dendritic cells with autologous anti-tetanus toxoid T lymphocytes results in a secretory switch, with induction of secretion of biologically active interleukin-18 and decrease of its intracellular content. Similarly, when dendritic cells are challenged with allospecific T cells a dramatic decrease of intracellular interleukin-18 content occurs, whereas no effects are observed after co-culture with autologous activated T cells. The induction of secretion can be mediated by engagement of **CD40** on **dendritic** cells, as indicated by the increased amount of interleukin-18 in **dendritic** cell supernatants after **CD40** triggering by anti-**CD40** **antibodies**. However, **CD40** engagement, unlike from antigen-specific T cells, does not result in reduced intracellular interleukin-18 content, suggesting that this decrease may be mediated by structure(s) involved in antigen recognition.

6/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11979865 BIOSIS NO.: 199900233178
Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand.
AUTHOR: Hirano Akio; Longo Dan L; Taub Dennis D; Ferris Douglas K; Young Lawrence S; Eliopoulos Arisitides G; Agathanggelou Angelo; Cullen Nicky; Macartney James; Fanslow William C; Murphy William J(a)
AUTHOR ADDRESS: (a)SAIC-Frederick, Bldg 567, Room 210, Frederick, MD**USA
JOURNAL: Blood 93 (9):p2999-3007 May 1, **1999**
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: **CD40** is present on B cells, monocytes, **dendritic** cells, and endothelial cells, as well as a variety of neoplastic cell types, including carcinomas. **CD40** stimulation by an **antibody** has previously been demonstrated to induce activation-induced cell death in aggressive histology human B-cell lymphoma cell lines. Therefore, we wanted to assess the effects of a recombinant soluble human CD40 ligand (srhCD40L) on human breast carcinoma cell lines. Human breast carcinoma cell lines were examined for CD40 expression by flow cytometry. CD40 expression could be detected on several human breast cancer cell lines and this could be augmented with interferon-gamma. The cell lines were then incubated with a srhCD40L to assess effects on in vitro growth. srhCD40L significantly inhibited the proliferation of the CD40+ human breast cancer cell lines. This inhibition could also be augmented with interferon-gamma. Viability was also affected and this was shown to be due to increased apoptosis of the cell lines in response to the ligand. Treatment of tumor-bearing mice was then performed to assess the in vivo efficacy of the ligand. Treatment of tumor-bearing SCID mice with the

ligand resulted in significant increases in survival. Thus, CD40 stimulation by its ligand directly inhibits human breast carcinoma cells in vitro and in vivo. These results suggest that srhCD40L may be of clinical use to inhibit human breast carcinoma growth.

6/7/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

07928705 EMBASE No: 1999402576
Generation of mature **dendritic** cells from a CD14sup + cell line (XS52) by IL-4, TNF-alpha, IL-1beta, and agonistic anti-**CD40** monoclonal **antibody**
Yamada N.; Katz S.I.
Dr. S.I. Katz, Dermatology Branch, National Cancer Institute, Building 10, Bethesda, MD 20892 United States
AUTHOR EMAIL: skatz@box-s.nih.gov
Journal of Immunology (J. IMMUNOL.) (United States) 15 NOV 1999, 163/10 (5331-5337)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33

We established a model system to generate mature dendritic cells (DC) from a GM-CSF-dependent cell line, XS52, which had been isolated from the epidermis of newborn BALB/c mice. Screening of various soluble factors revealed that IL-4 induces phenotypic maturation of XS52 (as evaluated by enhanced expression of class II, CD40, CD80, CD86, CD11c, and loss of expression of CD14) in a time-dependent manner. The addition of TNF-alpha, IL- 1beta, and agonistic anti-CD40 mAb further enhanced expression of these maturation markers. Consistent with their phenotypic maturation, these cells (termed XS-DC) exhibited potent Ag-presenting capacity to both naive and primed T cells. In addition, injection of hapten-conjugated XS-DC induced contact hypersensitivity in vivo, suggesting their potential as tools for vaccination. Expression of CD14 by the starting cell population, the requirement for GM-CSF and IL-4, and the relatively long culture period are the common characteristics shared between our cells and human monocyte-derived DC, whose analogues in mice have not been identified. Because large numbers of skin-associated mature DC devoid of other cell lineages are easily obtained, this model system may facilitate the study of molecular events associated with maturation of DC and the use of DC for immunization.

6/7/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

07729382 EMBASE No: 1999211200
Optimal stimulation of **dendritic** cells with anti-**CD40** **antibody**
Yokomizo H.; Okada Y.; Hashimoto M.; Kato H.; Endo S.; Yoshimatsu K.; Ogawa K.; Haga S.; Kajiwara T.
Dr. H. Yokomizo, Department of Surgery, Tokyo Women's Medical University, Daini Hospital, 2-1-10 Nishiogu, Arakawa-ku, Tokyo 116-8567 Japan
Biotherapy (BIOTHERAPY (JAPAN)) (Japan) 1999, 13/5 (633-635)
CODEN: BITPE ISSN: 0914-2223
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: JAPANESE SUMMARY LANGUAGE: ENGLISH; JAPANESE
NUMBER OF REFERENCES: 4

We have shown previously that **dendritic** cells (DC) stimulated with anti- **CD40** **antibody** have a potent anti-tumor effect. Here we

report on the optimal stimulation of DC with anti-CD40 antibody. This report shows that when DC is stimulated by anti-CD40 antibody the existence of GM-CSF induces downregulation of DC IL-12 production, expression of MHC class I molecules and expression of CD86. We think that the excessive GM-CSF leads to the proliferation of DC, not to the stimulation of DC with anti CD40 antibody.

6/7/6 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

07675635 EMBASE No: 1999150693
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
Kuniyoshi J.S.; Kuniyoshi C.J.; Lim A.M.; Wang F.Y.; Bade E.R.; Lau R.; Thomas E.K.; Weber J.S.
J.S. Kuniyoshi, Department of Molecular Microbiology, Univ. of S. California Sch. of Med., Los Angeles, CA 90033 United States
Cellular Immunology (CELL. IMMUNOL.) (United States) 10 APR 1999, 193/1 (48-58)
CODEN: CLIMB ISSN: 0008-8749
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 47

Dendritic cells (DC) are professional antigen-presenting cells which stimulate strong proliferative and cytolytic T cell responses. Stimulation of **CD40** on **dendritic** cells by its ligands and anti-**CD40 antibodies** induces maturation and enhances DC stimulatory ability. In order to understand the mechanism by which ligand:CD40 interactions augment DC function, we assessed the role of T cell stimulatory cytokines IL-12 and IL-15 in the function of DC stimulated with soluble trimeric CD40L, a recombinant fusion protein incorporating three covalently linked extracellular CD40L domains (huCD40LT). Peripheral blood derived DC treated with huCD40LT and/or IFN-gamma were used to stimulate T cell responses in vitro to specific antigens. DC treated with huCD40LT or IFN-gamma/huCD40LT stimulated enhanced T cell proliferation to CASTA, a soluble protein from C. albicans, induced T cells with augmented antigen-specific lysis, and increased the yield of antigen-specific IFN-gamma- producing T cells. IL-15 production by DC was enhanced in cultures treated with huCD40LT and correlated with expansion of antigen-specific cytolytic T cells. Addition of a neutralizing anti-IL-15 monoclonal antibody inhibited the expansion of viral and tumor antigen-specific T cells stimulated by IFN- gamma and huCD40LT-treated DC. In contrast, this enhanced stimulatory ability of DC did not appear to depend on synthesis of IL-12 since huCD40LT treatment stimulated the generation of antigen-specific cytokine producing and cytolytic T cells without increased IL-12 production. Addition of anti-IL-12 monoclonal antibody did not inhibit expansion of these cells. These data suggest that production of IL-15 but not IL-12 is an important factor in the enhanced immunostimulatory ability of huCD40LT-treated DC.

6/7/7 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

132346395 CA: 132(26)346395k JOURNAL
Obtaining of anti-human CD40 mono-clonal antibody with special functions and analysis of it's biological effects
AUTHOR(S): Zhou, Zhaohua; Wang, Jiangfang; Wang, Yuedan; Qiu, Yuhua; Pan, Jianzhong; Xie, Wei; Jiang, Lingyu; Zhang, Xueguang
LOCATION: Department of Immunology, Suzhou Medical College, Suzhou, Peop.

Rep. China, 215007
JOURNAL: Zhongguo Mianyixue Zazhi DATE: 1999 VOLUME: 15 NUMBER: 12
PAGES: 529-533 CODEN: ZMZAEE ISSN: 1000-484X LANGUAGE: Chinese
PUBLISHER: Zhongguo Mianyixue Zazhi Bianjibu
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: monoclonal antibody CD40 dendritic cell lymphocyte
DESCRIPTORS:
Cell proliferation...
B cell; prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects
Antibodies...
monoclonal; prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects
CD40(antigen)...
prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects
Dendritic cell...
prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects in relation to
B cell(lymphocyte)...
proliferation; prepn. of anti-human CD40 monoclonal antibody with special functions and anal. of its biol. effects

6/7/8 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

132048828 CA: 132(5)48828x JOURNAL
Generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody
AUTHOR(S): Yamada, Nobuo; Katz, Stephen I.
LOCATION: Dermatology Branch, National Cancer Institute, Bethesda, MD, 20892, USA
JOURNAL: J. Immunol. DATE: 1999 VOLUME: 163 NUMBER: 10 PAGES: 5331-5337 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English PUBLISHER: American Association of Immunologists
SECTION:
CA215005 Immunochemistry
IDENTIFIERS: dendritic cell maturation cytokine monoclonal Ig CD40
DESCRIPTORS:
T cell(lymphocyte)...
activation; generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody and
Skin...
epidermis, newborn; generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody
Antigen-presenting cell... CD14(antigen)... Cell differentiation... Dendritic cell... Interleukin 1.beta.... Interleukin 4... Tumor necrosis factors...
generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody
CD40(antigen)...
monoclonal Ig to; generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody
Immunoglobulins...
monoclonal, to CD40; generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody

Animal cell line...
XS52; generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody
CAS REGISTRY NUMBERS:
83869-56-1 generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-.alpha., IL-1.beta., and agonistic anti-CD40 monoclonal antibody and synergism with

6/7/9 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131270712 CA: 131(20)270712t JOURNAL
Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help
AUTHOR(S): Garcia de Vinuesa, Carola; MacLennan, Ian C. M.; Holman, Mary; Klaus, Gerry G. B.
LOCATION: Medical Research Council Center Immune Regulation, Univ. Birmingham, Birmingham, UK, B15 2TT
JOURNAL: Eur. J. Immunol. DATE: 1999 VOLUME: 29 NUMBER: 10 PAGES: 3216-3224 CODEN: EJIMAF ISSN: 0014-2980 LANGUAGE: English PUBLISHER: Wiley-VCH Verlag GmbH
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: Ig switch lipopolysaccharide antiCD40 antibody
DESCRIPTORS:
Antibodies...
anti-CD40 antibody enhanced IgG switch to polysaccharide without mimicking T cell help
Integrins...
antigens CD11c; dendritic cell redistribution and proliferation in anti-CD40 antibody enhanced IgG responses to polysaccharide
Integrins...
antigens Mac-1 (macrophage 1); macrophage redistribution and proliferation in anti-CD40 antibody enhanced IgG responses to polysaccharide
B cell(lymphocyte)... Dendritic cell... Macrophage... T cell(lymphocyte)...
cellular redistribution and proliferation in anti-CD40 antibody enhanced IgG responses to polysaccharide
Immunoglobulins...
D; anti-CD40 antibody enhanced IgG switch to polysaccharide without mimicking T cell help
Blood vessel...
endothelium; cellular redistribution and proliferation in anti-CD40 antibody enhanced IgG responses to polysaccharide
Immunoglobulins...
G; anti-CD40 antibody enhanced IgG switch to polysaccharide without mimicking T cell help
Immunoglobulins...
G3; anti-CD40 antibody enhanced IgG switch to polysaccharide without mimicking T cell help
Recombination,genetic...
Ig class switching; anti-CD40 antibody enhanced IgG responses to polysaccharide without mimicking T cell help
Immunoglobulins...
M; anti-CD40 antibody enhanced IgG switch to polysaccharide without mimicking T cell help

6/7/10 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131241814 CA: 131(18)241814x JOURNAL
Expression of gp130 molecule on dendritic cells
AUTHOR(S): Gu, Zongjiang; Wang, Yuedan; Qiu, Yuhua; Zhou, Zhaohua; Xie, Wei; Zhu, Huating; Zhang, Xueguang
LOCATION: Immunology Research Unit, Suzhou Medical College, Suzhou, Peop. Rep. China, 215007
JOURNAL: Zhongguo Mianyixue Zazhi DATE: 1999 VOLUME: 15 NUMBER: 5
PAGES: 196-198 CODEN: ZMZAEE ISSN: 1000-484X LANGUAGE: Chinese
PUBLISHER: Zhongguo Mianyixue Zazhi Bianjibu
SECTION:
CA215005 Immunochemistry
IDENTIFIERS: gp130 glycoprotein monocyte differentiation dendritic cell
DESCRIPTORS:
Dendritic cell... Interleukin 4... Monocyte... Tumor necrosis factors...
expression of gp130 mol. on dendritic cells
Cell differentiation...
monocyte; expression of gp130 mol. on dendritic cells
Interleukin 6 receptors...
receptor-assocd. glycoprotein gp130, gp130; expression of gp130 mol. on dendritic cells
CD40(antigen)...
stimulating monoclonal antibody; expression of gp130 mol. on dendritic cells
CAS REGISTRY NUMBERS:
83869-56-1 expression of gp130 mol. on dendritic cells

6/7/11 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131128995 CA: 131(10)128995u JOURNAL
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector
AUTHOR(S): Tillman, Bryan W.; De Gruijl, Tanja D.; Luykx-De Bakker, Sylvia A.; Scheper, Rik J.; Pinedo, Herbert M.; Curiel, Tyler J.; Gerritsen, Winald R.; Curiel, David T.
LOCATION: Gene Therapy Program, University of Alabama, Birmingham, AL, 35294, USA
JOURNAL: J. Immunol. DATE: 1999 VOLUME: 162 NUMBER: 11 PAGES: 6378-6383 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English PUBLISHER: American Association of Immunologists
SECTION:
CA215010 Immunochemistry
CA203XXX Biochemical Genetics
IDENTIFIERS: dendritic cell transgene CD40 adenovirus vector
DESCRIPTORS:
Proteins,specific or class...
fiber-knob; maturation of dendritic cells accompanies high-efficiency gene transfer by adenoviral vector targeted by bispecific antibody to CD40 and fiber-knob
Adenoviridae... CD40(antigen)... Dendritic cell... Transduction,genetic... Transgene... Virus vectors...
maturation of dendritic cells accompanies high-efficiency gene transfer by adenoviral vector targeted by bispecific antibody to CD40 and fiber-knob
Antibodies...
monoclonal, bispecific; maturation of dendritic cells accompanies high-efficiency gene transfer by adenoviral vector targeted by bispecific antibody to CD40 and fiber-knob

6/7/12 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

131017746 CA: 131(2)17746u JOURNAL
Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody
AUTHOR(S): Markees, T. G.; Phillips, N. E.; Gordon, E. J.; Noelle, R. J.; Maliszewski, C.; Mordes, J. P.; Greiner, D. L.; Rossini, A. A.
LOCATION: University of Massachusetts Medical School, Worcester, MA, 01605, USA
JOURNAL: Transplant. Proc. DATE: 1999 VOLUME: 31 NUMBER: 1/2 PAGES: 884-885 CODEN: TRPPA8 ISSN: 0041-1345 PUBLISHER ITEM IDENTIFIER: 0041-1345(98)01817-X LANGUAGE: English PUBLISHER: Elsevier Science Inc.
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: skin allograft dendritic cell CD154 monoclonal antibody
DESCRIPTORS:
Transplant and Transplantation...
allotransplant, skin; dendritic cells and anti-CD154 monoclonal antibody prolong survival of
Skin...
allotransplant; dendritic cells and anti-CD154 monoclonal antibody prolong survival of
Glycoproteins,specific or class...
CD40-L (antigen CD40 ligand); dendritic cells and anti-CD154 monoclonal antibody prolong skin allograft survival
Dendritic cell...
dendritic cells and anti-CD154 monoclonal antibody prolong skin allograft survival
Antibodies...
monoclonal; dendritic cells and anti-CD154 monoclonal antibody prolong skin allograft survival

6/7/13 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129329705 CA: 129(25)329705g PATENT
Receptor protein and its use
INVENTOR(AUTHOR): Nishi, Kazunori; Shintani, Atsushi; Horiguchi, Takashi
LOCATION: Japan,
ASSIGNEE: Takeda Chemical Industries, Ltd.
PATENT: European Pat. Appl. ; EP 873998 A2 DATE: 19981028
APPLICATION: EP 98303190 (19980424) *JP 97109798 (19970425) *JP 97251867 (19970917)
PAGES: 65 pp. CODEN: EPXXDW LANGUAGE: English CLASS: C07K-014/705A; C07K-016/28B; C12N-015/12B DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE; MC; PT; IE; SI; LT; LV; FI; RO
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: dendritic cell receptor protein ligand antibody
DESCRIPTORS:
Diseases(animal)...
acute bacterial periostitis; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflamma
Encephalitis...
acute viral; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
Immunological diseases...
allergic; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and

treating cancer, AIDS, infections, inflammation, etc.
Antigens... Proteins(specific proteins and subclasses)...
Apo-2 ligand; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
Pneumonia...
bacterial; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
CD antigens...
CD27, ligand; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
Chemistry...
chem. compds.; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
Adult respiratory distress syndrome... AIDS(disease)... Antibodies... Asthma... Autoimmune diseases... cDNA sequences... CD40 ligand... Chronic lymphocytic leukemia... Chronic myelogenous leukemia... Dendritic cell... DNA... Fas ligand... Glomerulonephritis... Infection... Inflammation... Insulin dependent diabetes mellitus... Ligands... Lymphotoxin... Melanoma ... Monoclonal antibodies... Multiple myeloma... Non-Hodgkin's lymphoma... Peptic ulcer... Protein sequences... Receptors... Sepsis... Test kits... Tuberculosis... Tumor necrosis factor .alpha.... Tumors(animal)...
dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
Tumor necrosis factor receptors...
family; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
CD30(antigen)...
ligand; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
Antigens...
OX-40, ligand; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
Receptors...
4-1BB, ligand; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
CAS REGISTRY NUMBERS:
215170-30-2 amino acid sequence; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating disease
9061-61-4 dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating cancer, AIDS, infections, inflammation, etc.
215170-31-3 nucleotide sequence; dendritic cell surface receptor protein of TNF receptor family and monoclonal antibody for screening compds. for preventing and treating disease

6/7/14 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

127261653 CA: 127(19)261653q JOURNAL
Antibodies against sialophorin (CD43) enhance the capacity of dendritic cells to cluster and activate T lymphocytes
AUTHOR(S): Fanales-Belasio, Emanuele; Zambruno, Giovanna; Cavani, Andrea;

Girolomoni, Giampiero
LOCATION: Laboratories Immunology Molecular Cell Biology, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy
JOURNAL: J. Immunol. DATE: 1997 VOLUME: 159 NUMBER: 5 PAGES: 2203-2211 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English PUBLISHER: American Association of Immunologists
SECTION:
CA215010 Immunochemistry
IDENTIFIERS: CD43 dendritic cell T lymphocyte activation
DESCRIPTORS:
Internalization... Translation(genetic)...
anti-CD43 antibodies stimulate CD43 internalization by dendritic cells
CD40(antigen)... CD80(antigen)... CD86(antigen)... HLA-DR antigen...
ICAM-1(cell adhesion molecule)...
anti-CD43 antibodies stimulate expression of adhesion/costimulatory mols. in dendritic cells
Cell adhesion... Dendritic cell... Leukosialin... T cell activation...
antibodies against CD43 enhance the capacity of dendritic cells to cluster and activate T lymphocytes
Langerhans' cell...
CD43 expression on Langerhans' cells
CD antigens...
CD83; anti-CD43 antibodies stimulate expression of adhesion/costimulatory mols. in dendritic cells

6/7/15 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

127094110 CA: 127(7)94110b PATENT
Therapeutic applications for the anti-T-BAM) (CD40-L) monoclonal antibody 5c8
INVENTOR(AUTHOR): Yellin, Michael J.; Lederman, Seth; Chess, Leonard; Karpusas, Mihail N.; Thomas, David W.
LOCATION: USA
ASSIGNEE: Trustees of Columbia University In the City of New York; Biogen, Incorporated
PATENT: PCT International ; WO 9720063 A1 DATE: 19970605
APPLICATION: WO 96US19172 (19961127) *US 566258 (19951201) *US 567391 (19951201) *US 637323 (19960422)
PAGES: 144 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/00A; G01N-033/53B; G01N-033/567B; A61K-039/395B; A61K-031/00B; A01N-037/18B
DESIGNATED COUNTRIES: AU; CA; JP; MX DESIGNATED REGIONAL: AT; BE; CH; DE ; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
SECTION:
CA215001 Immunochemistry
IDENTIFIERS: CD40 ligand monoclonal antibody therapy
DESCRIPTORS:
Transplant rejection...
allo-; therapeutic applications for the anti-CD40-L monoclonal antibodies in relation to
Liver diseases...
fibrosis; therapeutic applications for the anti-CD40-L monoclonal antibodies in relation to
Chimeric antibodies... Humanized antibodies... Immunoglobulin fragments...
therapeutic applications for the anti-CD40-L monoclonal antibodies
Arthritis... Asbestosis... Atherosclerosis... Autoimmune diseases... Hepatitis... Multiple myeloma... Osteoarthritis... Pneumoconiosis... Pulmonary fibrosis... Reperfusion injury... Rheumatoid arthritis... Scleroderma...
therapeutic applications for the anti-CD40-L monoclonal antibodies in relation to
CD40 ligand...

therapeutic applications for the anti-CD40-L monoclonal antibody 5c8
CD40(antigen)... Cell activation... Dendritic cell... Keratinocyte...
Protein sequences...
therapeutic applications for the anti-CD40-L monoclonal antibody 5c8 in relation to
Basophil...
therapeutic applications for the anti-CD40-L monoclonal antibody 5c8 in relation to basophil activation
Vascular endothelium...
therapeutic applications for the anti-CD40-L monoclonal antibody 5c8 in relation to endothelial cell activation
Fibroblast...
therapeutic applications for the anti-CD40-L monoclonal antibody 5c8 in relation to fibroblast activation
Macrophage activation...
therapeutic applications for the anti-CD40-L monoclonal antibody 5c8 in relation to macrophage activation
T cell activation...
therapeutic applications for the anti-CD40-L monoclonal antibody 5c8 in relation to T-cell activation
Monoclonal antibodies...
5c8; therapeutic applications for the anti-CD40-L monoclonal antibody 5c8

6/7/16 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

123110095 CA: 123(9)110095a JOURNAL
Stimulation of germinal center B lymphocyte proliferation by an FDC-like cell line, HK
AUTHOR(S): Kim, Han-Soo; Zhang, Xinhong; Klyushnenkova, Elena; Choi, Yong Sung
LOCATION: Lab. Cell. Immunol., Alton Ochsner Med. Foundation, New Orleans, LA, 70121, USA
JOURNAL: J. Immunol. DATE: 1995 VOLUME: 155 NUMBER: 3 PAGES: 1101-9
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English
SECTION:
CA215010 Immunochemistry
IDENTIFIERS: B cell proliferation follicular dendritic cell
DESCRIPTORS:
Animal cell line...
HK; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antigens,CD38... Apoptosis... Leukocyte,dendritic cell... Lymph node,germinal center... Lymphocyte,B-cell... Lymphokines and Cytokines,interleukin 4...
stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK
Antibodies...
to IgM or CD40; stimulation of germinal center B lymphocyte proliferation by an follicular dendritic cell-like cell line, HK

6/7/17 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

10444967 99443397 PMID: 10515374
Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
Lu L; Li W; Zhong C; Qian S; Fung J J; Thomson A W; Starzl T E

Thomas E. Starzl Transplantation Institute, and Department of Surgery, University of Pittsburgh, Pennsylvania 15213, USA.
Transplantation (UNITED STATES) Sep 27 **1999**, 68 (6) p747-57, ISSN 0041-1337 Journal Code: 0132144
Contract/Grant No.: AI41011; AI; NIAID; DK 29961; DK; NIDDK; DK49745; DK; NIDDK
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
BACKGROUND: We previously reported the association among donor leukocyte chimerism, apoptosis of presumedly IL-2-deficient graft-infiltrating host cells, and the spontaneous donor-specific tolerance induced by liver but not heart allografts in mice. Survival of the rejection-prone heart allografts in the same strain combination is modestly prolonged by the pretransplant infusion of immature, costimulatory molecule-(CM) deficient donor dendritic cells (DC), an effect that is markedly potentiated by concomitant CM blockade with anti-CD40L (CD154) monoclonal antibody (mAb). We investigated whether the long survival of the heart allografts in the pretreated mice was associated with donor leukocyte chimerism and apoptosis of graft-infiltrating cells, if these end points were similar to those in the spontaneously tolerant liver transplant model, and whether the pretreatment effect was dependent on sustained inhibition of CM expression of the infused immature donor DC. In addition, apoptosis was assessed in the host spleen and lymph nodes, a critical determination not reported in previous studies of either spontaneous or "treatment-aided" organ tolerance models. METHODS: Seven days before transplantation of hearts from B10 (H-2b) donors, 2x10(6) donor-derived immature DC were infused i.v. into C3H (H-2k) recipient mice with or without a concomitant i.p. injection of anti-CD40L mAb. Donor cells were detected posttransplantation by immunohistochemical staining for major histocompatibility complex class II (I-Ab) in the cells of recipient lymphoid tissue. CM expression was determined by two-color labeling. Host responses to donor alloantigen were quantified by mixed leukocyte reaction, and cytotoxic T lymphocyte (CTL) assays. Apoptotic death in graft-infiltrating cells and in areas of T-dependent lymphoid tissue was visualized by terminal deoxynucleotidyltransferase-catalyzed dUTP-digoxigenin nick-end labeling and quantitative spectrofluorometry. Interleukin-2 production and localization were estimated by immunohistochemistry. RESULTS: Compared with control heart transplantation or heart transplantation after only DC administration, concomitant pretreatment with immature donor DC and anti-CD40L mAb caused sustained elevation of donor (I-Ab+) cells (microchimerism) in the spleen including T cell areas. More than 80% of the I-Ab+ cells in combined treatment animals also were CD86+, reflecting failure of the mAb to inhibit CD40/ CD80/CD86 up-regulation on immature DC in vitro after their interaction with host T cells. Donor-specific CTL activity in graft-infiltrating cells and spleen cell populations of these animals was present on day 8, but decreased strikingly to normal control levels by day 14. The decrease was associated with enhanced apoptosis of graft-infiltrating cells and of cells in the spleen where interleukin-2 production was inhibited. The highest levels of splenic microchimerism were found in mice with long surviving grafts (>100 days). In contrast, CTL activity was persistently elevated in control heart graft recipients with comparatively low levels of apoptotic activity and high levels of interleukin-2. CONCLUSION: The donor-specific acceptance of rejection-prone heart allografts by recipients pretreated with immature donor DC and anti-CD40L mAb is not dependent on sustained inhibition of donor DC CM (CD86) expression. Instead, the pretreatment facilitates a tolerogenic cascade similar to that in spontaneously tolerant liver recipients that involves: (1) chimerism-driven immune activation, succeeded by deletion of host immune responder cells by apoptosis in the spleen and allograft that is linked to interleukin-2 deficiency in both locations and (2) persistence of comparatively large numbers of donor-derived leukocytes. These tolerogenic mechanisms are thought to be generic, explaining the tolerance

induced by allografts spontaneously, or with the aid of various kinds of immunosuppression.
Record Date Created: 19991105

6/7/18 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

10054934 99029732 PMID: 9814595
CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis.
Laman J D; De Boer M; Hart B A
Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), Leiden, The Netherlands.
Developmental immunology (ENGLAND) **1998**, 6 (3-4) p215-22, ISSN 1044-6672 Journal Code: 9200624
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
The interactions of CD40 and CD40L have been known for some time to critically regulate B-cell responses with respect to proliferation, isotype switching, **antibody** production, and memory formation. More recent findings demonstrated that **CD40** can be expressed on several other antigen-presenting cell (APC) types such as macrophages, **dendritic** cells, and fibroblasts. This expression of **CD40** regulates T-cell-APC interaction and is centrally involved in a wide array of inflammatory events. Here, currently available data are reviewed demonstrating that CD40-CD40L interactions are operational in two chronic inflammatory clinical conditions, namely, multiple sclerosis and atherosclerosis. The functional correlates of these interactions are discussed in the light of recent other findings, shedding light on the multiple effects of CD40-CD40L interactions. (50 Refs.)
Record Date Created: 19990127

6/7/19 (Item 3 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09845430 98259414 PMID: 9597126
CD40 and CD154 in cell-mediated immunity.
Grewal I S; Flavell R A
Howard Hughes Medical Institute, and Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Annual review of immunology (UNITED STATES) **1998**, 16 p111-35, ISSN 0732-0582 Journal Code: 8309206
Document type: Journal Article; Review; Review, Academic
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
CD40-CD154-mediated contact-dependent signals between B and T cells are required for the generation of thymus dependent (TD) humoral immune responses. CD40-CD154 interactions are however also important in many other cell systems. **CD40** is expressed by a large variety of cell types other than B cells, and these include **dendritic** cells, follicular **dendritic** cells, monocytes, macrophages, mast cells, fibroblasts, and endothelial cells. **CD40**- and CD154-knockout mice and **antibodies** to **CD40** and CD154 have helped to elucidate the role of the CD40-CD154 system in immune responses. Recently published studies indicate that CD40-CD154 interactions can influence T cell priming and T cell-mediated effector functions; they can also upregulate costimulatory molecules and activate macrophages, NK cells, and endothelia as well as participate in organ-specific autoimmune disease, graft rejection, and even atherosclerosis. This review focuses on the role of the CD40-CD154 system

in the regulation of many newly discovered functions important in inflammation and cell-mediated immunity. (115 Refs.)
Record Date Created: 19980805

6/7/20 (Item 4 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09767011 98208256 PMID: 9548477
Identification of two distinct populations of dendritic cells in afferent lymph that vary in their ability to stimulate T cells.
Howard C J; Sopp P; Brownlie J; Kwong L S; Parsons K R; Taylor G
The Institute for Animal Health, Compton, Near Newbury, United Kingdom. Chris.Howard@BBSRC.AC.UK
Journal of immunology (Baltimore, Md. : 1950) (UNITED STATES) Dec 1 **1997**, 159 (11) p5372-82, ISSN 0022-1767 Journal Code: 2985117R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Immunofluorescent staining and flow cytometric analysis of dendritic cells from cattle afferent lymph has established that within the afferent lymph veiled cells (ALVC) there are two phenotypically distinct, major populations. One is CD11a+, CD5+, CD21- and expresses the bovine WC10 (workshop cluster 10) molecule and the Ag recognized by mAb CC81 but is not recognized by mAbs CC149 and IL-A24. The second ALVC subpopulation is CD11a-, CD5-, CD21+/-, workshop cluster 10- and is not recognized by mAb CC81 but is recognized by mAb CC149. Thus, the two populations, which can be identified by staining for CD11a, are defined by the differential expression of a number of Ag. The ALVC populations had differing capacities to stimulate T cells. CD11a- ALVC were more effective at stimulating proliferative responses in allogeneic CD4+ T cells and CD8+ T cells. This was not related to binding of CTLA4Ig or CD40L fusion proteins, implying similar levels of expression of their ligands, CD80 and CD86 or CD40. Both subsets were able to present OVA to resting memory CD4+ T cells, indicating that both were able to take up and process soluble native protein. In contrast, the CD11a- ALVC were more effective in presenting respiratory syncytial virus Ag to resting CD4+ T cells. Considering the central role of dendritic cells in the initiation of immune responses in naive animals, the two cell types may have different roles in the induction of primary responses induced following infection or immunization.
Record Date Created: 19980420

6/7/21 (Item 5 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09652283 98082887 PMID: 9422424
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
Lu L; Li W; Fu F; Chambers F G; Qian S; Fung J J; Thomson A W
Thomas E. Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh, Pennsylvania 15213, USA..
Transplantation (UNITED STATES) Dec 27 **1997**, 64 (12) p1808-15, ISSN 0041-1337 Journal Code: 0132144
Contract/Grant No.: R01 AI41011; AI; NIAID; R01 DK 49745; DK; NIDDK
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
BACKGROUND: Failure of costimulatory molecule-deficient donor dendritic cells (DCs) to induce indefinite allograft acceptance may be a result of the 'late" up-regulation of these molecules on the DCs after interaction

with host T cells. Ligation of CD40 on antigen-presenting cells by its cognate ligand CD40L is thought to induce expression of CD80 (B7-1) and CD86 (B7-2). We examined the influence of anti-CD40L monoclonal antibody (mAb) on the capacity of donor-derived DC progenitors to induce long-term allograft survival. METHODS: High purity DC progenitors were grown from B10 (H2b) mouse bone marrow in granulocyte-macrophage colony-stimulating factor and transforming growth factor beta1 (TGFbeta1). Mature DC were propagated in granulocyte-macrophage colony-stimulating factor and interleukin-4. Their phenotype was characterized by flow cytometric analysis and their function by mixed leukocyte reactivity. Anti-donor cytotoxic T lymphocyte activity in grafts and spleens of vascularized heart allograft recipients was also assessed. RESULTS: The TGFbeta3-cultured cells were (1) DEC 205-positive, MHC class II-positive, CD80dim, CD86dim, and CD40dim, (2) poor stimulators of naive allogeneic T-cell proliferation, and (3) able to prolong significantly B10 cardiac allograft survival in C3H (H2k) recipients when given (2 x 10[6] i.v.) 7 days before organ transplantation (median survival time [MST] 26 days vs. 12 days in controls, and 5 days in interleukin-4 DC-treated animals). Their allostimulatory activity was further diminished by addition of anti-CD40L mAb at the start of the mixed leukocyte cultures. Anti-CD40L mAb alone (250 microg/mouse, i.p.; day -7) did not prolong cardiac graft survival (MST 12 days). In contrast, TGFbeta-cultured DCs + anti-CD40L mAb extended graft survival to a MST of 77 days, and inhibited substantially the anti-donor cytotoxic T lymphocyte activity of graft-infiltrating cells and host spleen cells assessed 8 days after transplant. CONCLUSIONS: The CD40-CD40L pathway appears important in regulation of allogeneic DC-T-cell functional interaction in vivo; its blockade increases markedly the potential of costimulatory molecule-deficient DCs of donor origin to induce long-lasting allograft survival.
Record Date Created: 19980122

6/7/22 (Item 6 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09499504 97392352 PMID: 9250584
Functional role of CD40 and its ligand.
van Kooten C; Banchereau J
Department of Nephrology, Leiden University Hospital, The Netherlands.
International archives of allergy and immunology (SWITZERLAND) Aug **1997**, 113 (4) p393-9, ISSN 1018-2438 Journal Code: 9211652
Document type: Journal Article; Review; Review Literature
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
CD40, a cell surface receptor which belongs to the TNF-R family, was first identified and functionally characterized on B lymphocytes. In recent years, CD40 has been found expressed on other cells, including monocytes, dendritic cells, endothelial cells and epithelial cells and is now thought to play a more general role in immune regulation. The present paper reviews recent developments about CD40, with main emphasis on: (1) structure and expression of CD40 and its ligand; (2) CD40 signal transduction; (3) in vitro function of CD40 on different cell types, and (4) in vivo functions of CD40/CD40L interactions. (47 Refs.)
Record Date Created: 19970905

6/7/23 (Item 7 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09369928 97244166 PMID: 9088975
CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells.
Bjorck P; Banchereau J; Flores-Romo L
Schering-Plough Laboratory for Immunological Research, Dardilly, France.

International immunology (ENGLAND) Mar **1997**, 9 (3) p365-72,
ISSN 0953-8178 Journal Code: 8916182
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Dendritic cells (DC) are cells of the hematopoletic system specialized in capturing antigens and initiating T cell-mediated immune responses. We show here that human DC generated in vitro by culturing CD34+ cord blood progenitor cells in granulocyte macrophage colony stimulating factor plus tumor necrosis factor-alpha express the Fas antigen (APO-1, CD95) and undergo apoptosis upon triggering of Fas by mAb. However, only a proportion of the cells die in response to Fas ligation, an observation that may be related to the virtual absence of the bcl-2 protein in about half of the cells. Ligation of DC CD40 by culture on CD40L-transfected fibroblastic cells up-regulates the expression of bcl-2 and, concomitantly, renders DC virtually resistant to Fas-induced apoptosis. Parallel experiments with mature, interdigitating dendritic cells (IDC) isolated from tonsils revealed that IDC express Fas but do not enter into apoptosis following Fas ligation, a finding that may be explained by their high levels of bcl-2. Thus, upon encountering antigen-specific T cells, DC become resistant to Fas-induced apoptosis, as a consequence of CD40 ligation and possibly by mechanisms associated to the up-regulation of bcl-2 protein expression.
Record Date Created: 19971016

6/7/24 (Item 8 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08706619 96036887 PMID: 8526104
Human dendritic cells can drive CD40-activated sIgD+ B cells to mount mucosal-type humoral response.
Fayette J; Dubois B; Caux C; Banchereau J; Briere F
Schering-Plough, Laboratory for Immunological Research, Dardilly, France.
Advances in experimental medicine and biology (UNITED STATES) **1995**, 378 p401-3, ISSN 0065-2598 Journal Code: 0121103
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Record Date Created: 19960125

6/7/25 (Item 9 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08597420 95355838 PMID: 7629501
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
Sallusto F; Cella M; Danieli C; Lanzavecchia A
Basel Institute for Immunology, Switzerland.
Journal of experimental medicine (UNITED STATES) Aug 1 **1995**, 182 (2) p389-400, ISSN 0022-1007 Journal Code: 2985109R
Comment in J Exp Med. 1995 Aug 1;182(2) 283-8; Comment in PMID 7629494
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
We have previously demonstrated that human peripheral blood low density mononuclear cells cultured in granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 develop into dendritic cells (DCs) that are extremely efficient in presenting soluble antigens to T cells. To identify the mechanisms responsible for efficient antigen capture, we

studied the endocytic capacity of DCs using fluorescein isothiocyanate-dextran, horseradish peroxidase, and lucifer yellow. We found that DCs use two distinct mechanisms for antigen capture. The first is a high level of fluid phase uptake via macropinocytosis. In contrast to what has been found with other cell types, macropinocytosis in DCs is constitutive and allows continuous internalization of large volumes of fluid. The second mechanism of capture is mediated via the mannose receptor (MR), which is expressed at high levels on DCs. At low ligand concentrations, the MR can deliver a large number of ligands to the cell in successive rounds. Thus, while macropinocytosis endows DCs with a high capacity, nonsaturable mechanism for capture of any soluble antigen, the MR gives an extra capacity for antigen capture with some degree of selectivity for non-self molecules. In addition to their high endocytic capacity, DCs from GM-CSF + IL-4-dependent cultures are characterized by the presence of a large intracellular compartment that contains high levels of class II molecules, cathepsin D, and lysosomal-associated membrane protein-1, and is rapidly accessible to endocytic markers. We investigated whether the capacity of DCs to capture and process antigen could be modulated by exogenous stimuli. We found that DCs respond to tumor necrosis factor alpha, CD40 ligand, IL-1, and lipopolysaccharide with a coordinate series of changes that include downregulation of macropinocytosis and Fc receptors, disappearance of the class II compartment, and upregulation of adhesion and costimulatory molecules. These changes occur within 1-2 d and are irreversible, since neither pinocytosis nor the class II compartment are recovered when the maturation-inducing stimulus is removed. The specificity of the MR and the capacity to respond to inflammatory stimuli maximize the capacity of DCs to present infectious non-self antigens to T cells.

Record Date Created: 19950907

?

```
----  -----------
Cost is in DialUnits
? b 410
       26aug02 10:03:39 User208760 Session D2136.1
            $0.28    0.081 DialUnits File1
     $0.28  Estimated cost File1
     $0.01  TELNET
     $0.29  Estimated cost this search
     $0.29  Estimated total session cost   0.081 DialUnits

File 410:Chronolog(R)  1981-2002/Jul
       (c) 2002 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,399,154
       26aug02 10:03:54 User208760 Session D2136.2
            $0.00    0.071 DialUnits File410
     $0.00  Estimated cost File410
     $0.05  TELNET
     $0.05  Estimated cost this search
     $0.34  Estimated total session cost   0.151 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R)  1969-2002/Aug W2
         (c) 2002 BIOSIS
*File   5: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File  73:EMBASE  1974-2002/Aug W3
         (c) 2002 Elsevier Science B.V.
*File  73: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File 399:CA SEARCH(R)  1967-2002/UD=13708
         (c) 2002 AMERICAN CHEMICAL SOCIETY
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
  File 154:MEDLINE(R)  1990-2002/Aug W3
*File 154: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.

      Set  Items  Description
      ---  -----  -----------
? s (3(w)23)(10n)(antibod?)(10n)(Cd40)
         5899102  3
          553714  23
         1445964  ANTIBOD?
           15400  CD40
      S1       9  (3(W)23)(10N)(ANTIBOD?)(10N)(CD40)
? rd s1
...completed examining records
      S2       4  RD S1 (unique items)
? t s2/7/all

 2/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13060592   BIOSIS NO.: 200100267741
Regulation of iNOS expression and myocardial cell death: Mechanisms of
  allograft survival with CD40L deficiency.
AUTHOR: Shimizu Koichi(a); Rabkin Elena(a); Schoenbeck Uwe(a); Libby Peter
```

(a); Mitchell Richard N(a)
AUTHOR ADDRESS: (a)Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115**USA
JOURNAL: FASEB Journal 15 (4):pA670 March 7, 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Introduction: Previous studies showed that despite early moderate rejection, the absence of CD40L on recipient immune cells leads to long-term survival of complete allogeneic mismatched cardiac grafts. In this study, we examined mechanisms by which host CD40L depletion results in allograft survival. Methods and Results: Vascularized heterotopic cardiac transplantation was performed using total allogeneic mismatched combinations of wild type (WT) BALB/c (B/c, H-2d) and WT or CD40L-/- C57BL/6 (B6, H-2b) mice. By postoperative day 7, the histologic grade of parenchymal rejection (PR) in WT B/c allograft hearts was significantly greater for B6 WT than for B6 CD40L-/- recipients. PR scores were 3.13 +- 0.52 and 2.17 +- 0.41 (p = 0.0028) in WT (n = 8) and CD40L-/- (n = 6) recipient allografts, respectively. Immunohistochemistry showed that iNOS and peroxynitrite expression was markedly diminished, out of proportion to the diminished cellular infiltrate in CD40L-/- recipient allografts. Flow cytometry showed that Fas ligand expression on the graft infiltrating CD8+ T cells was significantly reduced in CD40L-/- compared to WT recipient allografts. Although TUNEL-positive graft infiltrating cells were present in similar numbers in grafts in WT and CD40L-/- allografts, TUNEL-positive donor myocardial cells were seen only in the WT recipient allografts. Caspase-3 activity was 30-fold higher in WT than in CD40L-/- recipient allografts on post-operative day 7. To confirm a role for Fas and NO-mediated pathways, transplants involving Fas-/- donor hearts and chronic administration of iNOS inhibitor (L-NIL) significantly prolonged allograft survival. In vitro, recombinant CD40L or **CD40** stimulating **antibody** (**3/23**) induced iNOS mRNA of IFN-gamma primed human monocytes or mouse peritoneal macrophages, respectively. Conclusions: This study demonstrates that both Fas-FasL interaction and iNOS-induced pathways may cooperate to cause donor myocyte death or dysfunction in acute allograft rejection. Host CD40L deficiency may induce long-term allograft survival by ameliorating FasL and iNOS expression.

2/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12666263 BIOSIS NO.: 200000419765
Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process.
AUTHOR: Mauri Claudia; Mars Lennart T; Londei Marco(a)
AUTHOR ADDRESS: (a)The Kennedy Institute of Rheumatology, Imperial College School of Medicine, 1 Aspenlea Road, London, W6 8LH**UK
JOURNAL: Nature Medicine 6 (6):p673-679 June, 2000
MEDIUM: print
ISSN: 1078-8956
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: The use of agonistic monoclonal antibody against CD40 has emerged as one the most effective ways to boost immune responses against infectious agents or to fight cancer. Here, we report that the same monoclonal **antibodies** against **CD40** (FGK45 and **3/23**) previously used to elicit protective immune responses treated the autoimmune inflammatory process of chronic collagen-induced arthritis in DBA/1-TCR-beta transgenic mice, as well as collagen-induced arthritis in DBA/1 mice, both animal models of rheumatoid arthritis. This study indicates that agonistic monoclonal antibody against CD40 can potentially be used to treat chronic autoimmune inflammatory processes.

2/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09436214 BIOSIS NO.: 199497444584
Properties of mouse CD40: Cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies.
AUTHOR: Hasbold Jhagvaral; Johnson-Leger Caroline; Atkins Chris J; Clark Edward A; Klaus Gerry G B(a)
AUTHOR ADDRESS: (a)Lab. Cellular Immunol., National Inst. Med. Res., London NW7 1AA**UK
JOURNAL: European Journal of Immunology 24 (8):p1835-1842 1994
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: We describe here the derivation of a rat monoclonal **antibody** (mAb) against mouse **CD40** (designated **3/23**), which stains 45-50% of spleen cells of adult mice, approximately 90% of which are B cells. Interestingly, some 5-10% of both CD4+ and CD8+ T cells in the spleens of (some, but not all) adult, unimmunized mice are also CD40+, whereas CD40+ cells were not detectable in the thymus, even following collagenase digestion. Some 35-40% of lymphoid cells in the bone marrow of adult mice are CD40+ and virtually an of these are B220+, and hence of the B cell lineage: triple-color flow cytometry showed that CD40 is expressed at low levels on some 30% of pre-B cells, at intermediate levels on 80% of immature B cells and on essentially all mature B cells in the bone marrow. These results, therefore, suggest that in the mouse CD40 is expressed relatively late during the process of B cell differentiation. The mAb induced marked up-regulation of major histocompatibility complex class II molecules, CD23 and B7.2 antigens on mature B cells. It also stimulated modest levels of DNA synthesis in mature B cells by itself: this was markedly enhanced by suboptimal concentrations of mitogenic (but not non-mitogenic) anti-mu and anti-delta mAb, and moderately enhanced by co-stimulation with interleukin-4. Hypercross-linking of CD40 (using biotinylated mAb and avidin) also enhanced the proliferative response to anti-CD40.

2/7/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

07681636 EMBASE No: 1999166742
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
French R.R.; Chan H.T.C.; Tutt A.L.; Glennie M.J.
M.J. Glennie, Lymphoma Research Unit, Tenovus Laboratory, General Hospital, Southampton SO16 6YD United Kingdom
AUTHOR EMAIL: M.J.Glennie@soton.ac.uk

Nature Medicine (NAT. MED.) (United States) 1999, 5/5 (548-553)
CODEN: NAMEF ISSN: 1078-8956
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 41

CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8sup + T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further **antibody** treatment. Thus, it seems that by treating mice with monoclonal **antibody** against **CD40**, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two **antibodies** against **CD40** (**3/23** and FGK-45) in three CD40sup + lymphomas (A20, A31 and BCLinf1) and gave partial protection in one of two CD40sup - lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8sup + T cells recovered from responding mice showed powerful cytotoxic activity against the target B- cell lymphoma in vitro.

```
? s (cd40)(10n)(antibod?)(dendritic)
           15400  CD40
               0  ANTIBOD?)(DENDRITIC)
      S3       0  (CD40)(10N)(ANTIBOD?)(DENDRITIC)
? s (cd40)(10n)(antibod?)(10n)(dendritic)
           15400  CD40
         1445964  ANTIBOD?
           80316  DENDRITIC
      S4      88  (CD40)(10N)(ANTIBOD?)(10N)(DENDRITIC)
? rd s4
...examined 50 records  (50)
...completed examining records
      S5      66  RD S4 (unique items)
? s s5 and py<2000
Processing
Processing
              66  S5
        39951254  PY<2000
      S6      25  S5 AND PY<2000
```